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Combined MET and BRAF inhibition showed clinical benefit in a patient with rectal 
cancer carrying BRAFV600E and MET amplification. However after four months, acquired 
resistance emerged and the patient deceased shortly after disease progression. The 
mechanism of resistance to this drug combination is unknown. 
 
Methods: 
We analysed plasma circulating tumour DNA obtained at progression by exome 
sequencing and digital PCR. MET gene and mRNA in situ hybridization analyses in two 
bioptic specimens obtained at progression were used to confirm plasma data. 
 
Results: 
We identified in plasma MET gene hyper-amplification as a potential mechanism 
underlying therapy resistance. Increased MET gene copy and transcript levels were 
detected in liver and lymph node metastatic biopsies. Finally, transduction of MET in 




We identified in a rectal cancer patient MET gene hyper-amplification as mechanism 
of resistance to dual BRAF and MET inhibition. 
 
Keywords: BRAF / colorectal cancer / crizotinib / drug resistance / target therapy / MET 
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The MET oncogene encodes for a receptor tyrosine kinase involved in the regulation 
of tumour growth, survival, angiogenesis, invasion and metastases (Birchmeier et al, 
2003; Raghav et al, 2012). Its amplification is associated with sensitivity to MET 
inhibition in preclinical models as well as in a subset of patients (Camidge et al, 
2014; Smolen et al, 2006). MET gene amplification may be present in subclones of 
tumour cells that are positively selected during anti-EGFR based therapy in both 
NSCLC and colorectal cancer (CRC) patients (Bardelli et al, 2013; Pietrantonio et 
al, 2016; Turke et al, 2010). MET amplification or copy gain occurs in a fraction of 
BRAF mutated tumors including CRC (Jardim et al, 2014; Pietrantonio et al, 2016). 
The combination of vemurafenib (BRAF inhibitor) with crizotinib (dual ALK-MET 
inhibitor) is being assessed in a phase I study (NCT01531361),  but  to  date  no  
mechanisms  of  primary  or  secondary  resistance  to combined BRAF and MET 
inhibitors have been  characterized  at  pre-clinical  or  clinical level. Here, for the first 
time, we identified a molecular mechanism of clinical resistance to BRAF and MET 
inhibition by analysis of ctDNA from plasma alongside tissue taken at progression to 
this combination therapy in a rectal cancer patient. 
 
 
MATERIALS AND METHODS 
 
Patient Care. The study involved a 48-year-old patient with BRAFV600E mutant 
microsatellite-stable mucinous metastatic rectal cancer. Biospecimens were collected 
in accordance with a Fondazione IRCCS Istituto Nazionale dei Tumori Review Board– 
approved protocol, to which the patient provided written informed consent, and all 
studies were conducted in accordance with the Declaration of Helsinki. The patient's 
insurance company covered the cost of crizotinib+vemurafenib off-label combination 
therapies, to which the patient gave written informed consent. CT scans were obtained 




(whole exome sequencing and digital PCR on plasma samples; DNA and RNA in 




Cell lines. WiDr parental cells were obtained from Dr René Bernards (Amsterdam, 
The Netherlands) in July 2011. The genetic identity of parental cell lines and their 
resistant derivatives was confirmed by short tandem repeat profiling (Cell ID System; 
Promega) at 10 different loci. Cell lines were tested and resulted negative for 
Mycoplasma contamination with the VenorGeM Classic Kit (Minerva Biolabs). WiDr 
METampl cell line was generated as previously described (Pietrantonio et al, 2016). 





The first part of this molecular case study was previously published and involved the 
same BRAF mutated metastatic rectal cancer patient who became resistant to 
combined BRAF and EGFR blockade (vemurafenib+panitumumab) due to the 
emergence of MET amplification. The patient was shifted from EGFR to MET inhibition, 
and received the combination of vemurafenib and crizotinib achieving an early 
response (Pietrantonio et al, 2016). Then, partial response was confirmed after 2 
months of treatment, although the computed tomography (CT) scan at 4 months 
showed progressive disease (PD) across all sites (Figure 1A). 
 
 
In order to uncover potential mechanisms of acquired resistance, whole exome next- 
generation sequencing analysis of plasma circulating tumour DNA (ctDNA) obtained 
prior to crizotinib and vemurafenib treatment and at PD was performed. DNA isolated 
from PBMC was used  to  remove  germline  variants  from  the  analysis.  The 
number of sequencing reads supporting the presence of a BRAFV600E mutation was 
comparable in the pre-treatment and post-resistance samples, indicating similar amounts 
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of tumour- derived circulating cell free DNA in both samples (Figure 1B). No acquired 
single nucleotide variants were observed in plasma ctDNA at PD (Supplementary 
Table S1). However, MET copy number variation (CNV) further increased in the plasma 
ctDNA sample obtained at progression (Figure 1B). 
In order to validate these findings, BRAFV600E mutation and MET gene copy were 
longitudinally monitored in plasma ctDNA by droplet digital PCR using 15 samples 
collected at regular intervals from initial receipt of vemurafenib+panitumumab (Figure 
1C). A rapid decrease in BRAFV600E mutation and MET CNV in ctDNA was observed 
within two weeks from the start of vemurafenib+crizotinib. The dynamics of mutant 
BRAFV600E alleles anticipated radiological progression, as mutant BRAF in plasma 
increased again as early as 8 weeks after starting therapy. At progression, the 
percentage of BRAFV600E alleles were comparable to the pre-treatment sample, while 
– proportionally – a notable increase in the number of MET copies was detected 
(Figure 1C), thus validating exome data. 
 
 
To corroborate MET hyper-amplification, and to  further  exclude  tumour  burden-related 
MET CNV, we performed gene copy number analysis by MET/CEP7 bright field in 
situ hybridization (ISH) in tissue specimens obtained before and after treatment. In 
the liver biopsy obtained after resistance to vemurafenib+panitumumab but prior to 
vemurafenib+crizotinib (Figure 2, indicated as baseline 2), heterogeneous MET gene 
copy number (ranging from 2 to 20) had previously been reported (Pietrantonio et 
al, 2016). Upon resistance to vemurafenib+crizotinib, the patient consented to liver and 
inguinal lymph node tumour biopsies, both of which displayed MET hyper-amplification 
by ISH. Of note, the pre- and post- treatment liver biopsies were taken from the 
same metastatic lesion. Exome analysis performed on DNA from the liver biopsy at 
resistance confirmed the presence of MET amplification and ruled out other genetic 
mechanisms of resistance (Supplementary Table S1). Collectively, the results in liquid 
and tissue biopsies suggest that clones with higher levels of MET gene amplification 
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had been selected by the treatment. 
 
Since evaluation of MET activation has recently been proposed to better correlate 
with transcription rather than protein expression due to the rapid  turnover  of  the  
activated protein (Bradley et al, 2016), we investigated MET transcript levels in 
tissues by RNA in situ hybridization (RNA ISH). While MET mRNA was undetectable 
in the rectal primary tumour tissue, low expression level was seen in the liver biopsy 
taken after vemurafenib+panitumumab. Notably, upon resistance to 




In order to test whether MET overexpression is causally responsible for resistance to 
vemurafenib+crizotinib combination treatment, we conducted in vitro forward genetic 
experiments. We previously reported that a BRAF mutant CRC cell line, WiDr, which 
also has increased MET gene copy number (WiDr-METampl), was sensitive to 
vemurafenib+crizotinib treatment  (Pietrantonio et al, 2016). We found that exogeneous 
hyper-expression of MET in the same WiDr-METampl cells  (called  WiDr-hyper  METampl, 
Figure 2B) could confer resistance to dual BRAF and MET inhibition and prevented 





Concomitant  inhibition  of  BRAF  and  MET  in  CRC  patients  with  BRAFV600E   and  
MET amplification  could  represent  a  rationale  therapeutic strategy (Pietrantonio  et al,  
2016).  Recent work correlated MET amplification with a higher prevalence of BRAFV600E 
tumours (Jardim et al, 2014), which may increase the impact of this combination. 
 
 
The patient reported in this work achieved 4 months of partial response under therapy 
with vemurafenib+crizotinib until drug resistance emerged. Our effort to uncover the gene 
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alteration(s) driving resistance was based on ctDNA plasma sequencing. This 
approach has the potential to capture the inter- and intra-tumour heterogeneity present 
in metastatic disease (Russo et al, 2016). Single nucleotide variants and CNV were 
comprehensively analysed by whole exome sequencing comparing plasma ctDNA taken 
prior to target treatment and at PD. No single nucleotide variants previously associated 
with resistance to BRAF inhibition in melanoma or CRC were observed (Ahronian et 
al, 2015; Hong et al, 2016; Oddo et al, 2016). We also did not detect secondary MET 
mutations affecting the crizotinib-binding region, which had been observed either by 
drug-protein co-crystal structure analysis or in MET amplified tumours after acquired 




In a previous study of a MET amplified gastric cancer cell line treated with 
increasing concentrations of MET inhibitors, resistance was correlated with increased  
MET amplification accompanied by increased KRAS expression (Cepero et al, 2010). 
Our analyses identified only MET hyper-amplification, detected both by ISH and 
mRNA ISH methodologies, as the most likely genetic alteration underlying clinical 
acquired resistance to BRAF and MET inhibition. 
Even when precision oncology is successful, the efficacy of targeted strategies is 
generally transient. Since the patient died about two months following disease 
progression, we speculate that MET hyper-amplification coupled with BRAFV600E 
mutation not only conferred  resistance  to  vemurafenib+crizotinib,  but  could  be  
also  responsible  for  the particularly aggressive disease behaviour. Elucidating the 
molecular mechanisms underlying secondary resistance may help in designing further 
lines of therapy (Bahcall et al, 2016; Pietrantonio et al, 2016; Russo et al, 2016). We 
believe that the traits associated with the extremely high level of MET expression 
shown by the resistant tumour in this study could have been exploited as a Achilles’ 
heel to rationally test as a further salvage line novel anti-MET antibody-drug 
conjugates, such as ABBV-399, which showed promising activity in MET amplified 
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cancer cells and non-small cell lung cancer patients (Strickler et al, 2016; Wang et al, 
2017). However, the rapid deterioration of patient conditions prevented administration of 
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Figure 1. Emergence of MET gene hyper-amplification in plasma circulating 
tumour DNA of a BRAFV600E metastatic colorectal cancer patient upon 
progression to crizotinib and vemurafenib combinatorial treatment. 
A) Clinical course of the disease during treatment with vemurafenib+crizotinib. 
Computed tomography scans document the disease status before treatment (left 
panel), after the initial response (middle panel) and at disease progression (right 
panel). B) Exome analysis of   circulating   tumour   DNA   (ctDNA)   by next-generation   
sequencing   (NGS).   Mutant BRAFV600E allele frequencies of 46% and 50% were seen 
in the baseline 2 plasma sample and at resistance, respectively, indicating similar 
amounts of ctDNA in both samples. MET copy number variation (CNV) is increased 
when comparing ctDNA before therapy with vemurafenib+crizotinib and after disease 
progression. C) Analysis of ctDNA by digital droplet PCR (ddPCR). Time kinetics of 
the percentage of BRAFV600E alleles (red line) or copies of MET gene copy number 
(blue line) show a decrease of both circulating markers during patient response to 
vemurafenib+crizotinib. At radiological disease progression, the percentage of 
BRAFV600E alleles were comparable to the pre-treatment sample, while – 
proportionally - a notable increase in MET gene copy number was detected. 
Datapoints represent mean ± SD of 2 independent observations, each performed in 




Figure 2. MET gene hyper-amplification and MET mRNA expression emerge in a 
patient with BRAFV600E rectal cancer and confer resistance to BRAF and MET 
dual inhibition in WiDr cells. In situ hybridization analyses for MET gene and 
mRNA levels were performed on the primary tumour (baseline 1, panels A1 and 
B1), a liver biopsy 
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obtained upon resistance to vemurafenib+panitumumab but before 
vemurafenib+crizotinib (baseline 2, panels A2 and B2), as well as liver (panels A3 and 
B3) and inguinal lymph node (panels A4 and B4) biopsies obtained upon acquired 
resistance to vemurafenib+crizotinib. A) Dual colour bright field in situ hybridization 
(ISH) for MET gene (black dots) and CEP7 (red dots). The baseline sample obtained 
prior to targeted treatments does not show MET amplification, even if a few clones 
display gain of MET gene copy number, with 18% of neoplastic cells bearing >5 MET 
gene copy number (A1). The sample obtained at acquired resistance to 
vemurafenib+panitumumab but prior to vemurafenib+crizotinib (baseline 2) shows MET 
amplification, with a mean gene copy number of 8.8 (range 2-20) (A2). Upon acquired 
resistance  to  vemurafenib+crizotinib, tumour cells display MET ‘hyper-amplification’, 
with a further increase of MET gene copy number in both liver re-biopsy (A3 – 
multiple copies and small and large clusters) and inguinal lymph node biopsy (A4 – 
small and large clusters). In situ hybridization for MET mRNA MET gene transcription is 
below level of detection (score = 0) in baseline 1 sample (B1); while an increased 
staining of MET gene transcription (score = 1) is present in the liver biopsy upon 
acquired resistance to vemurafenib+panitumumab (B2). This is further increased in 
samples obtained upon resistance to vemurafenib+crizotinib (B3-B4), with evidence of 
strong MET mRNA overexpression (score = 3 in liver biopsy; score = 4 in lymph 
node biopsy). Scale bar represent 12.5 µm. B) BRAFV600E mutant WiDr parental or its 
MET amplified derivative cell line (WiDr-METampl) were transduced with either control 
(empty)   or   MET–expressing   lentiviral   vector   (here   called   WiDr   hyper-
METampl), respectively. Protein extraction and Western blotting with total MET antibodies 
revealed a gradient of MET protein expression among the three different cell lines. 
HSP90 is reported for normalization purposes. C) Cell viability by ATP assay of WiDr 
empty, METampl  and hyper-METampl  cells after treatment for 72 hours with the indicated 
molar concentrations of vemurafenib in association with constant 0.2 μM crizotinib. D) 
WiDr empty, METampl and hyper METampl were treated for 72 hours with 1 μM 
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vemurafenib and/or 0.2 μM crizotinib in mono or combinatorial therapies. CellTox green 
cytoxicity assay was performed to identify cells with compromised membrane integrity 
characteristic of cell death. Data are expressed as fold change relative to DMSO 
treated control cells. Results represent mean ± SD of 2 independent observations, each 
performed in duplicate or triplicate. Statistical differences in BRAF mutant cell viability 
or cytotoxicity between METampl and hyper- METampl cells was determined with the Mann-
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Solid tumour tissues (rectum, liver and inguinal lymph node) and whole blood were 
collected in accordance with an Institutional Review Board–approved protocol, to which 
the patient provided written informed consent, and all studies were conducted in 
accordance with the Declaration of Helsinki. Patient was still alive when biospecimens 
were obtained. 
A minimum of 10 ml of whole blood samples were obtained during therapy by direct 
venipuncture in antecubital area of the arm (or from central venous catheter devices) 
directly on standard EDTA tubes.  Plasma was separated within 5 h through two different 
centrifugation steps (the first at room temperature for 10 min at 1,600g and the second at 
3,000g for the same time and temperature), obtaining up to 3 ml of plasma. PBMC were 
also obtained which served as a reference control for germ-line genomic DNA. Plasma 
samples and PBMC were frozen and shipped in dry ice to IRCCS Candiolo, (Turin, Italy) 
and stored at -80°C upon arrival until ctDNA extraction. Solid tumour tissues were 
formalin-fixed in 10% neutral buffered formalin for 24 hours according to routine 
procedures and paraffin-embedded. 
 
DNA extraction from plasma, PBMC and tissue 
Germline DNA was extracted from PBMC using ReliaPrep Tissue Kit (Promega, #A2051). 
ctDNA  for ddPCR analysis was extracted from 1 ml of plasma using the Maxwell® RSC 
ccfDNA Plasma Kit (Promega, #AS1480) with the automated Maxwell® RSC Instrument 
(Promega) according to the manufacturer’s instructions. ctDNA samples for Next 
Generation Sequencing analysis were extracted from plasma using the QIAamp 
Circulating Nucleic Acid Kit (Qiagen, #55114) according to the manufacturer’s instructions 
and DNA yield measured with the  Qubit® dsDNA HS Assay Kit (Thermo Fisher Scientific, 
#Q32851). Tissue DNA was extracted by ReliaPrep gDNA Tissue Miniprep System 
(Promega) according to manufacturer’s directions. 
 
Whole exome sequencing and bioinformatics  
Libraries were prepared with Nextera Rapid Capture Exome Kit (Illumina Inc., San Diego, 
CA, USA), according to the manufacturer’s protocol. Preparation of libraries was 
performed using up to 150 ng of plasma ctDNA and 100 ng of PBMC and fresh tissue 
DNA. DNA from PBMC and fresh tissues was fragmented using transposons, adding 
simultaneously adapter sequences, while ctDNA libraries preparation was performed using 
NEBNext® Ultra™ DNA Library Prep Kit for Illumina® (New England BioLabs Inc., Ipswich 
MA), with optimized protocol. DNA from PBMC and fresh tissues after the tagmentation 
step, and ctDNA were used as template for subsequent PCR to introduce unique sample 
barcodes. Fragments’ size distribution of the DNA was assessed using the 2100 
Bioanalyzer with a High Sensitivity DNA assay kit (Agilent Technologies, Santa Clara, CA). 
Equal amount of DNA libraries were pooled and subjected to targeted panel hybridization 
capture. Libraries were then sequenced using an Illumina Next-Seq-500 sequencer 
(Illumina Inc., San Diego, CA, USA).  In order to analyze only good quality sequences, all 
nucleotides in the reads with a Phred quality score less than 30 were removed. FastQ files 
were then mapped to the human reference (assembly hg19) using the BWA-mem 
algorithm (Li & Durbin, 2010) and PCR duplicates were removed using the RMDUP 
command of SAMtools package (Li et al, 2009). Mutational discovery analyses were 
performed by a custom NGS pipeline, in order to call somatic variations, when supported 
by at least 1% allelic frequency and 5% significance level obtained with a Fisher test, as 
previously described (Siravegna et al, 2015). To identify insertions and deletions (indels), 
we further analyzed the alignment files by comparing pre-treatment and post-treatment 
samples using Pindel software (Ye et al, 2009). The indels that were presents in germline 
sample or supported less than 4 reads were filtered out. Mutations and indels were 
annotated by a custom script printing out gene information, number of normal and mutated 
reads, the allelic frequencies and the variation effect. Each of these entries was associated 
with the corresponding number of occurrences in the COSMIC database (Forbes et al, 
2015). Gene copy number (GCN) was obtained by calculating the ratio of the median gene 
read depth to the median read depth of all coding regions. Alterations of tumour sample 
with respect to normal were obtained by considering the ratio of the corresponding GCNs. 
 
Droplet Digital PCR (ddPCR) 
Circulating free DNA isolated from plasma was amplified using ddPCR™ Supermix for 
Probes (Bio-Rad) using BRAFV600E assay (PrimePCR™ ddPCR™ Mutation Assay, Bio-
Rad, #dHsaCP2000027) and MET vs EIF2C1 (reference) for gene number copies 
(PrimePCR ddPCR Copy Number Assay, Bio-Rad, # dHsaCP250032- #dHsaCP1000002). 
ddPCR was then performed according to manufacturer’s protocol and the results reported 
as number of copies and/or percentage or Fractional Abundance of mutant DNA alleles to 
total (mutant plus wild type) DNA alleles. 8 to 10 µl of DNA template was added to 10 µl of 
ddPCR™ Supermix for Probes (Bio-Rad) and 2 µl of the primer/probe mixture. Droplets 
were generated using Automated Droplet Generator (Bio-Rad, #186-4101) where the 
reaction mix was added together with Droplet Generation Oil for Probes (Bio-Rad, # 
#1864110). Droplets were then transferred to a 96 well plate (Eppendorf, # H 0030 129 
504) and then thermal cycled with the following conditions: 5 minutes at 95°C, 40 cycles of 
94°C for 30s, 55°C for 1 minute followed by 98°C for 10 minutes (Ramp Rate 2°C/sec). 
Droplets were analyzed with the QX200™ Droplet Reader for fluorescent measurement of 
FAM and HEX probes. Gating was performed based on positive and negative controls, 
and mutant populations were identified. The ddPCR data were analyzed with 
QuantaSoft™ analysis software (Bio-Rad) to obtain CNV and Fractional Abundance of the 
mutant DNA alleles in the wild-type (WT)/normal background. The quantification of the 
target molecule was presented as number of total copies (mutant plus WT) per sample in 
each reaction. Fractional Abundance is calculated as follows: F.A. % = 
(Nmut/(Nmut+Nwt))*100), where Nmut is number of mutant events and Nwt is number of 
WT events per reaction. ddPCR analysis of normal control (from cell lines) and no DNA 
template controls were always included. Samples with positive events that were too low 
were repeated at least twice in independent experiments to validate the obtained results.  
 
MET DNA silver In situ hybridization (SISH) 
Bright field dual-color SISH analysis was performed on 3 μm formalin fixed and paraffin 
embedded (FFPE) tissue sections by using the MET DNP Probe along with the 
Chromosome 7 DIG Probe (Ventana Medical Systems, Tucson, AZ, USA) on a 
BenchMark Ultra Platform (Ventana Medical Systems) according to the manufacture’s 
protocol.  
 
RNA in situ hybridisation (ISH) studies 
MET mRNA expression was studied in FFPE tissue sections by means of ISH using the 
target probe Homo sapiens MET (Hs-MET) (Cat. No. 310051 - sequence region 1236–
2257, Advanced Cell Diagnostics, Inc., Hayward, CA). For each case a negative control 
probe (bacterial gene 4-hydroxy-tetrahydrodipicolinate reductase [DapB]; # 310043, 
sequence region 139–989, Advanced Cell Diagnostics) and a positive control probe for 
evidence of preserved RNA (housekeeping gene ubiquitin C [UbC] #310041 - sequence 
region 342–1503, Advanced Cell Diagnostics) was included. ISH was performed manually 
using the RNAscope 2.5 High Definition detection kit (brown) (Advanced Cell Diagnostics) 
in accordance with the manufacturer’s instructions. 
Briefly, 5 µm FFPE tissue sections were incubated with hydrogen peroxide for 10 minutes 
at room temperature (RT). The slides then were boiled in Target Retrieval 1X buffer for 45 
minutes, followed by incubation with Protease Plus for 20-30 minutes at 40°C, and then 
hybridised with the relevant probes for two hours at 40°C, followed by successive 
incubations with Amp1-Amp6 reagents, colour development with 3,3’-diaminobenzine 
(DAB), and counterstaining with haematoxylin. Positive staining signals were identified as 
brown, punctuate dots in the cytoplasm and/or nucleus. 
 
MET mRNA ISH scoring 
MET mRNA was analysed by using a scoring system that categorizes the cases into five 
grades depending on the number of dots visualised under a bright-field microscope: 0 = no 
staining or <1 dot every 10 cells; 1+: 1-3 dots/cell; 2+: 4-10 dots/cell with very few dot 
clusters; 3+: >10 dots/cell with <10% of positive cells having dot clusters; and 4+: >10 
dots/cell with >10% of positive cells having dot clusters. 
 
Cell lines and Drugs 
WiDr parental and METampl cell lines were cultured at 37°C and 5% CO2 in RPMI 1640 
(Invitrogen), supplemented with 10% fetal bovine serum, 2 mM L-glutamine and antibiotics 
(100 U/ml penicillin and 100 mg/ml streptomycin). Vemurafenib was purchased from 
Sequoia Chemicals; crizotinib was from ChemieTek. 
 
Western Blot analysis 
Total cellular proteins were extracted by lysing cells in boiling Laemmli buffer (1% SDS, 50 
mM Tris-HCl [pH 7.5], 150 mM NaCl). The following primary antibodies were used: anti-
MET (rabbit polyclonal, clone D1C2, 1:1000, Cell Signaling Technology) and Actin (goat 
polyclonal, clone I-19, Santa Cruz Biotechnology; 1:3000). 
 
Viral Infection 
Lentiviral vector stock were produced by transient transfection of the pCCL-MET wild-type 
or lenti-control plasmid (a gift of Elisa Vigna, IRCCS, Candiolo, Turin) the packaging 
plasmid MDLg/pRRE and pRSV.REV, and the vesicular stomatitis virus (VSV) envelope 
plasmid pMD2.VSV-G (25, 2.5, 6.25 and 9 µg, respectively, for 15-cm dishes) in HEK-
293T cells in presence of 1mM/L sodium butyrate (Sigma) and 10 ng/ml of Doxicicline. 
Cells were tranduced in six well plates (3 x 105 per well in 2 ml of medium) in the presence 
of polybrene (8 µg/ml) (Sigma). 
 
Drug proliferation assays 
Cell proliferation experiments were carried out in 96-well plates in duplicate. Cells were 
plated (3,000 cells/well) in 100 µl complete growth medium. At 24 hours post-seeding, 100 
µl of serum-free medium was manually added to the cells. Vemurafenib and crizotinib were 
added directly on the plate by TECAN D300e digital dispenser (HP). After 72 hours’ 
treatment cell viability was assessed by ATP content using CellTiter-Glo Luminescent 
Assay (Promega). Viability was normalized as a percentage of control untreated cells. 
Data from growth-inhibition assays were plotted using the nonlinear regression curve fit 
modelling from GraphPad Prism-5 (GraphPad Software).  
Cell proliferation over time from day 0 to day 5 was estimated by ATP content using 
CellTiter-Glo Luminescent Cell Viability Assay (Promega) following manufacturer’s 
instructions and according the experimental procedure describe above. 
 
 
Cytotoxicity assays  
For cytotoxicity assays cells were seeded at 4,000 cells/well in 96-well black optical-
bottom plates (Nunc, Life Technologies). After 24 hours, cells were treated with 
vemurafenib (1 μM) and/or crizotinib (0.2 μM) in mono or combinatorial therapies. The 
CellTox Green cytotoxicity assay was performed according to manufacturer instructions 
and fluorescence was read by TECAN Spark 10M plate reader at 535 nm. As toxicity 
control, Lysis Solution was added (4 μl per 100 μl of cells) 30 minutes prior to reading. 
Subsequently, the amount of viable cells for each well was quantified by CellTiter-Glo 
Luminescent Assay (Promega). Data were first normalized to the amount of cells and after 
to untreated control. 
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Legend to Supplementary Table: 
 
Supplementary Table S1. List of gene mutation hotspots previously involved in 
resistance to BRAF inhibition or the crizotinib binding site of MET. For each hotspot, 
the numbers of reads supporting each allele in pre-treatment and post-treatment samples 
are shown. All counts were obtained from alignments files: reads from whole exome 
sequencing were mapped to the human reference (assembly hg19), PCR duplicates were 
removed and all bases with a Phred score less than 30 are filtered out. 
 
Legend to Supplementary Figure: 
 
Supplementary Figure S1. Hyper-METampl cells under vemurafenib and crizotinib 
treatment proliferate similarly to the untreated cells. Proliferation rate of WiDr METampl 
and hyper-METampl cells was measured by ATP assay. Cells were cultured from day 0 to 
day 5 in absence or presence of the following drug combination: 1 μM vemurafenib and 
0.2 μM crizotinib. Data are expressed as relative light units. Results represent mean ± SD 
of 2 independent observations, each performed in triplicate. Statistical differences in BRAF 
mutant cell viability between METampl and hyper-METampl cells was determined with the 
Mann-Whitney U test (*P < .05).  






























COORDINATES GENE AA_CHANGE REF A1 C1 G1 T1 A2 C2 G2 T2 A2 C2 G2 T2
chr10:123258034 FGFR2 p.N549 A 590 1 0 0 776 0 0 0 742 1 0 0
chr10:123274774 FGFR2 p.C382 A 651 0 0 0 673 0 0 0 682 1 0 0
chr10:123274794 FGFR2 p.Y375 T 0 0 2 657 0 0 1 662 1 0 1 696
chr10:123274803 FGFR2 p.S372 G 0 0 703 0 0 0 678 1 0 0 693 2
chr10:123279503 FGFR2 p.K310 T 0 0 1 420 0 0 0 402 0 0 0 374
chr10:123279674 FGFR2 p.P253 G 0 0 259 0 0 0 299 0 0 0 237 0
chr10:123279677 FGFR2 p.S252 G 0 0 231 0 0 0 229 1 0 0 189 0
chr10:43609096 RET p.C618 T 0 0 1 296 0 0 1 260 1 0 3 372
chr10:43609102 RET p.C620 T 0 0 0 322 0 0 0 289 1 0 1 388
chr10:43609936 RET p.C630 T 1 0 1 494 0 0 1 528 0 0 0 636
chr10:43609940 RET p.D631 A 433 1 0 0 437 1 0 0 509 3 0 0
chr10:43609948 RET p.C634 T 0 0 1 482 0 0 1 545 0 0 3 624
chr10:43609949 RET p.C634 G 0 0 601 2 0 0 594 0 0 0 797 1
chr10:43609950 RET p.C634 C 0 564 0 0 0 538 0 0 4 747 0 0
chr10:43613840 RET p.E768 G 0 0 465 1 0 0 431 0 0 1 762 0
chr10:43615567 RET p.V882 A 454 0 0 0 458 0 0 0 552 1 0 0
chr10:43615568 RET p.A883 G 0 0 497 1 0 0 460 1 0 0 610 5
chr10:43615569 RET p.A883 C 1 470 0 0 1 440 0 0 1 570 0 0
chr10:43617416 RET p.M918 T 0 0 2 581 0 0 0 778 0 0 0 770
chr10:89624245 PTEN p.E7 G 0 0 308 0 0 0 385 1 0 0 433 0
chr10:89624255 PTEN p.S10 G 0 0 300 0 0 0 370 1 0 0 421 1
chr10:89624263 PTEN p.K13 A 303 0 0 0 431 0 1 0 470 0 0 1
chr10:89624266 PTEN p.R14 A 287 0 0 0 408 0 0 0 431 1 0 1
chr10:89624270 PTEN p.R15 G 0 0 283 0 0 0 392 0 0 0 454 0
chr10:89624271 PTEN p.R15 A 283 1 0 0 397 0 0 0 467 1 0 0
chr10:89624273 PTEN p.Y16 A 279 0 0 0 404 1 0 1 455 2 0 0
chr10:89624275 PTEN p.Q17 C 2 294 0 0 0 402 2 0 2 457 0 0
chr10:89685271 PTEN p.F56 T 0 0 0 338 0 0 0 508 0 0 0 298
chr10:89685275 PTEN p.L57 T 0 0 0 390 0 0 0 517 0 0 0 337
chr10:89685281 PTEN p.S59 C 0 371 0 2 0 480 0 0 1 324 0 0
chr10:89685287 PTEN p.H61 A 379 0 0 0 504 0 0 0 338 0 0 0
chr10:89685300 PTEN p.Y65 C 0 387 0 0 1 475 0 0 0 342 0 1
chr10:89685301 PTEN p.K66 A 379 0 0 0 507 0 0 0 351 0 0 0
chr10:89685303 PTEN p.K66 G 0 0 391 0 0 0 476 2 0 0 382 0
chr10:89685307 PTEN p.Y68 T 0 1 0 387 0 0 1 479 0 0 0 409
chr10:89685308 PTEN p.Y68 A 393 0 0 0 478 0 0 0 405 0 0 0
chr10:89692830 PTEN p.C105 G 0 0 506 0 0 0 681 0 0 0 736 0
chr10:89692831 PTEN p.C105 T 2 0 0 486 0 0 1 702 0 2 1 731
chr10:89692835 PTEN p.D107 G 0 0 525 0 0 0 698 0 0 0 752 2
chr10:89692839 PTEN p.L108 T 0 0 0 571 0 1 0 783 0 0 1 803
chr10:89692844 PTEN p.Q110 C 0 526 0 0 2 673 1 1 0 697 0 0
chr10:89692847 PTEN p.W111 T 1 0 0 569 0 0 0 771 3 0 1 753
chr10:89692848 PTEN p.W111 G 0 0 545 0 2 0 685 3 0 0 727 0
chr10:89692850 PTEN p.L112 C 0 582 0 0 0 753 0 0 0 769 0 0
chr10:89692851 PTEN p.L112 T 0 0 0 576 0 0 0 791 0 0 0 781
chr10:89692877 PTEN p.A121 G 0 0 591 1 1 0 734 2 0 0 768 2
chr10:89692878 PTEN p.A121 C 0 586 0 0 2 789 0 0 2 802 0 0
chr10:89692880 PTEN p.I122 A 591 1 0 0 845 1 0 0 795 2 0 0
chr10:89692881 PTEN p.I122 T 2 0 0 576 0 0 0 816 0 0 1 785
chr10:89692882 PTEN p.I122 T 0 0 0 596 0 0 0 842 0 0 0 823
chr10:89692883 PTEN p.H123 C 0 599 0 0 0 774 0 0 2 785 0 0
chr10:89692886 PTEN p.C124 T 0 1 0 614 0 0 0 833 0 0 1 792
chr10:89692887 PTEN p.C124 G 0 0 623 0 0 0 777 0 2 0 789 1
chr10:89692889 PTEN p.K125 A 607 0 0 0 843 0 0 0 786 1 0 0
chr10:89692892 PTEN p.A126 G 0 0 614 1 0 0 804 3 0 0 820 1
chr10:89692893 PTEN p.A126 C 1 617 0 0 2 769 0 0 0 772 0 0
chr10:89692896 PTEN p.G127 G 0 0 625 2 0 0 807 2 0 0 760 1
chr10:89692900 PTEN p.K128 G 0 0 634 0 0 0 785 0 0 0 758 0
chr10:89692901 PTEN p.G129 G 0 0 591 0 2 0 782 4 0 0 754 1
chr10:89692904 PTEN p.R130 C 1 620 0 0 0 799 0 0 0 732 1 0
chr10:89692905 PTEN p.R130 G 0 0 601 3 0 0 797 0 0 0 708 1
chr10:89692910 PTEN p.G132 G 0 0 596 0 0 0 751 1 0 0 693 0
chr10:89692911 PTEN p.G132 G 0 0 609 0 0 0 785 0 1 0 781 0
chr10:89692913 PTEN p.V133 G 0 1 622 0 0 0 829 0 0 1 776 1
chr10:89711875 PTEN p.G165 G 0 0 323 2 1 0 450 0 0 0 374 1
chr10:89711876 PTEN p.G165 G 0 0 345 0 0 0 469 4 0 0 380 1
chr10:89711881 PTEN p.T167 A 340 0 0 0 519 0 0 0 422 0 0 0
chr10:89711891 PTEN p.S170 G 0 0 404 2 0 0 528 0 0 0 371 0
chr10:89711893 PTEN p.Q171 C 0 396 0 0 1 553 0 0 0 382 0 0
chr10:89711894 PTEN p.Q171 A 393 1 0 0 564 0 0 0 398 0 0 0
chr10:89711899 PTEN p.R173 C 0 409 0 0 1 522 0 0 2 375 0 0
chr10:89711900 PTEN p.R173 G 1 0 422 0 0 0 526 2 0 0 375 0
chr10:89711902 PTEN p.Y174 T 0 0 0 420 0 0 0 579 0 0 0 397
chr10:89711912 PTEN p.Y177 A 414 0 0 0 581 0 0 0 435 0 0 0
chr10:89717615 PTEN p.Q214 C 0 366 0 0 0 369 1 0 1 409 0 0
chr10:89717678 PTEN p.E235 G 2 0 448 0 0 3 426 0 0 0 453 0
chr10:89717699 PTEN p.E242 G 0 0 433 0 0 0 438 0 0 0 489 0
chr10:89717708 PTEN p.Q245 C 0 414 0 0 2 444 0 0 0 493 0 0
chr10:89717712 PTEN p.P246 C 0 416 0 0 0 382 0 0 1 510 0 0
chr10:89717726 PTEN p.G251 G 0 0 401 0 0 0 395 0 0 0 483 0
chr10:89717727 PTEN p.G251 G 0 0 415 0 0 0 421 1 0 0 515 0
chr10:89717729 PTEN p.D252 G 0 0 423 1 0 0 427 0 0 0 464 0
chr10:89717730 PTEN p.D252 A 425 0 0 0 462 0 0 0 495 2 0 0
chr10:89717733 PTEN p.I253 T 0 0 0 401 0 0 0 460 0 0 1 491
chr10:89717741 PTEN p.E256 G 0 0 402 0 0 0 433 0 0 0 463 0
chr10:89717756 PTEN p.Q261 C 2 388 0 0 0 431 0 0 0 436 0 0
chr10:89717762 PTEN p.K263 A 377 0 0 0 467 0 0 0 444 0 0 0
chr10:89720711 PTEN p.E288 G 0 0 231 0 0 0 342 0 0 0 313 1
chr10:89720720 PTEN p.E291 G 0 0 259 1 0 0 382 1 0 0 326 1
chr10:89720741 PTEN p.Q298 C 2 321 0 0 4 473 0 0 0 370 0 0
chr10:89720841 PTEN p.D331 A 344 0 0 0 484 0 0 0 390 1 0 0
chr10:89720851 PTEN p.N334 C 0 323 0 0 0 422 0 0 1 411 0 0
chr10:89720852 PTEN p.R335 C 0 323 0 0 0 416 0 0 1 391 0 1
chr10:89720857 PTEN p.Y336 C 0 314 0 0 0 447 0 0 1 409 0 0
chr10:89720864 PTEN p.P339 C 0 311 0 0 0 399 0 0 0 394 0 0
chr10:89720870 PTEN p.F341 T 0 0 0 311 0 0 0 435 0 0 0 431
chr11:108117798 ATM p.R337 C 1 846 0 0 0 974 0 0 3 590 0 2
chr11:108119823 ATM p.V410 T 0 0 2 849 1 0 0 1184 0 0 1 671
chr11:108123551 ATM p.P604 C 0 696 0 0 0 860 1 0 1 474 0 0
chr11:108137973 ATM p.E848 G 0 0 772 4 0 0 939 1 0 0 604 0
chr11:108138003 ATM p.F858 T 0 0 0 702 2 0 1 964 1 0 0 580
chr11:108155132 ATM p.A1309 G 1 0 914 1 0 0 883 0 0 0 604 0
chr11:108170476 ATM p.I1681 A 601 0 0 0 693 0 0 0 695 0 0 0
chr11:108170479 ATM p.D1682 G 0 0 605 0 0 0 671 0 0 0 702 1
chr11:108172421 ATM p.A1742 G 0 0 794 0 0 1 971 1 0 0 594 1
chr11:108173640 ATM p.L1794 C 1 761 0 0 0 1004 0 0 0 575 0 0
chr11:108180945 ATM p.V1941 G 2 0 814 0 0 0 1029 1 0 0 633 0
chr11:108200958 ATM p.Q2442 A 910 0 1 0 1238 1 0 0 785 0 0 0
chr11:108200961 ATM p.R2443 G 0 0 944 1 0 0 1086 0 0 0 749 0
chr11:108204681 ATM p.T2666 A 647 0 0 0 806 0 0 0 491 0 0 0
chr11:108205769 ATM p.G2695 G 0 0 907 2 0 0 1182 0 0 0 871 1
chr11:108206594 ATM p.D2725 A 714 0 0 0 926 0 0 0 700 5 0 0
chr11:108218084 ATM p.I2888 T 0 0 0 719 0 0 0 918 0 0 0 522
chr11:108218089 ATM p.L2890 C 0 697 0 0 1 818 0 0 5 506 0 0
chr11:108225590 ATM p.T2947 A 718 1 0 1 1019 0 0 0 713 3 0 0
chr11:108236086 ATM p.R3008 C 0 863 0 0 0 1068 0 0 2 784 0 0
chr11:108236087 ATM p.R3008 G 0 0 856 0 0 0 1057 2 0 0 779 1
chr11:108236203 ATM p.R3047 C 3 530 0 0 0 634 0 2 0 445 0 0
chr11:533871 HRAS p.E62 T 1 0 0 304 0 0 0 305 0 0 2 341
chr11:533873 HRAS p.Q61 C 2 309 0 0 1 278 0 0 2 336 0 0
chr11:533874 HRAS p.Q61 T 0 0 0 288 0 0 0 281 0 0 0 313
chr11:533875 HRAS p.Q61 G 0 0 303 0 0 0 275 0 0 0 289 1
chr11:534242 HRAS p.H27 A 125 2 88 0 201 1 119 0 247 1 84 0
chr11:534285 HRAS p.G13 C 0 253 0 0 0 328 0 0 0 352 0 0
chr11:534286 HRAS p.G13 C 1 239 0 0 0 309 0 1 2 318 0 0
chr11:534288 HRAS p.G12 C 0 248 0 0 1 316 0 0 0 338 0 0
chr11:534289 HRAS p.G12 C 1 239 0 0 1 308 0 0 0 317 0 0
chr11:534290 HRAS p.A11 G 0 0 238 0 0 0 309 0 0 0 305 0
chr12:112888139 PTPN11 p.T52 C 1 1002 0 0 2 1344 1 0 1 853 0 0
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chr12:112888156 PTPN11 p.N58 A 990 2 0 0 1388 2 0 0 851 1 0 0
chr12:112888162 PTPN11 p.G60 G 0 0 1093 1 0 0 1403 0 2 0 832 3
chr12:112888163 PTPN11 p.G60 G 0 0 1115 0 0 0 1436 0 0 0 880 2
chr12:112888165 PTPN11 p.D61 G 2 0 1166 1 2 0 1517 2 0 0 877 0
chr12:112888166 PTPN11 p.D61 A 1186 0 0 0 1592 0 0 0 940 0 0 1
chr12:112888189 PTPN11 p.E69 G 0 0 1268 1 0 0 1569 0 0 0 873 2
chr12:112888195 PTPN11 p.F71 T 3 0 0 1298 0 0 0 1702 0 0 0 960
chr12:112888197 PTPN11 p.F71 T 0 0 0 1243 0 1 0 1614 0 1 0 908
chr12:112888198 PTPN11 p.A72 G 0 0 1343 2 0 0 1588 0 0 0 923 1
chr12:112888199 PTPN11 p.A72 C 0 1261 0 2 5 1517 1 0 2 861 0 1
chr12:112888202 PTPN11 p.T73 C 6 1287 0 0 4 1518 0 0 1 893 0 0
chr12:112888210 PTPN11 p.E76 G 1 0 1303 0 0 0 1416 4 0 0 900 1
chr12:112888211 PTPN11 p.E76 A 1321 0 2 0 1608 3 1 0 986 0 0 0
chr12:112926852 PTPN11 p.P491 C 0 1096 0 0 2 1296 0 0 1 1152 0 0
chr12:112926884 PTPN11 p.S502 T 1 0 1 1043 0 0 2 1299 0 0 4 980
chr12:112926885 PTPN11 p.S502 C 0 1273 0 1 2 1550 1 0 1 1149 0 0
chr12:112926888 PTPN11 p.G503 G 0 0 1280 0 0 0 1450 1 0 0 1125 1
chr12:112926908 PTPN11 p.Q510 C 0 1337 0 0 2 1558 0 1 3 1241 1 0
chr12:121431403 HNF1A p.R203 C 0 351 0 0 0 342 0 0 0 405 0 0
chr12:121431413 HNF1A p.W206 G 0 0 313 1 0 0 355 0 0 1 388 1
chr12:121431414 HNF1A p.W206 G 0 0 309 1 0 0 329 1 0 0 374 0
chr12:121431416 HNF1A p.G207 G 1 0 323 1 0 0 331 0 0 0 405 1
chr12:121431428 HNF1A p.Q211 A 279 0 0 0 300 1 0 0 335 0 0 0
chr12:121432032 HNF1A p.T260 C 0 408 0 0 0 359 0 0 0 406 1 0
chr12:121432040 HNF1A p.R263 C 0 400 0 0 1 371 0 0 1 393 0 0
chr12:121432068 HNF1A p.R272 G 0 0 381 0 0 0 351 0 0 0 352 1
chr12:121432070 HNF1A p.K273 A 392 0 0 0 389 0 1 1 352 0 0 0
chr12:25378560 KRAS p.A146 T 1 0 0 588 0 0 0 766 0 0 0 667
chr12:25378561 KRAS p.A146 G 0 0 588 0 0 0 728 2 0 0 652 1
chr12:25378562 KRAS p.A146 C 0 570 0 0 1 701 0 0 0 629 0 0
chr12:25378647 KRAS p.K117 T 0 0 0 757 0 0 0 943 1 0 0 680
chr12:25378648 KRAS p.K117 T 0 0 0 774 2 0 0 968 0 0 1 669
chr12:25378649 KRAS p.K117 T 0 0 0 754 0 0 0 912 0 0 0 640
chr12:25380275 KRAS p.Q61 T 0 0 1 499 1 0 0 718 0 0 2 611
chr12:25380276 KRAS p.Q61 T 0 0 0 495 0 0 1 713 0 0 0 607
chr12:25380277 KRAS p.Q61 G 0 0 487 0 0 0 676 1 0 0 589 0
chr12:25380278 KRAS p.G60 A 411 0 0 0 572 1 0 0 528 2 0 0
chr12:25380281 KRAS p.A59 T 0 0 0 471 0 0 0 641 0 0 0 541
chr12:25380282 KRAS p.A59 G 0 0 475 0 0 1 615 3 0 0 563 1
chr12:25380283 KRAS p.A59 C 0 457 0 0 4 582 0 0 0 565 0 0
chr12:25380285 KRAS p.T58 G 0 0 465 0 0 0 588 0 0 0 559 1
chr12:25398255 KRAS p.Q22 G 0 0 535 1 0 0 718 1 2 0 739 3
chr12:25398262 KRAS p.L19 C 0 543 0 0 3 710 0 0 2 768 0 0
chr12:25398266 KRAS p.A18 G 0 0 509 1 0 0 688 0 0 0 727 2
chr12:25398276 KRAS p.G15 C 0 497 0 0 0 640 0 0 3 759 0 0
chr12:25398279 KRAS p.V14 C 0 479 0 0 0 603 0 0 2 690 0 0
chr12:25398280 KRAS p.G13 G 0 0 465 1 2 0 579 0 0 0 731 1
chr12:25398281 KRAS p.G13 C 0 484 0 0 0 603 0 0 1 743 0 0
chr12:25398282 KRAS p.G13 C 0 463 0 0 0 607 0 0 1 744 0 0
chr12:25398283 KRAS p.G12 A 409 0 0 0 568 0 0 0 672 1 0 0
chr12:25398284 KRAS p.G12 C 0 463 0 1 0 612 0 0 0 769 0 0
chr12:25398285 KRAS p.G12 C 0 482 0 0 0 603 0 0 0 714 0 0
chr12:25398287 KRAS p.A11 G 0 0 442 0 0 0 567 0 1 0 735 0
chr12:25398288 KRAS p.A11 C 0 481 0 0 0 614 1 0 1 777 0 0
chr12:25398295 KRAS p.V8 T 0 0 0 451 0 0 0 609 0 0 0 727
chr13:28592620 FLT3 p.Y842 T 0 0 0 321 0 0 0 320 0 0 0 251
chr13:28592635 FLT3 p.M837 A 330 0 0 0 337 0 0 0 305 0 0 0
chr13:28592636 FLT3 p.M837 T 0 0 0 339 0 0 0 350 0 0 0 323
chr13:28592637 FLT3 p.I836 G 0 0 347 1 0 0 342 0 0 0 321 0
chr13:28592638 FLT3 p.I836 A 349 0 0 0 354 0 0 0 320 0 0 0
chr13:28592639 FLT3 p.I836 T 1 0 1 350 0 0 0 371 0 0 0 329
chr13:28592640 FLT3 p.D835 A 345 0 0 0 371 0 0 0 332 0 0 0
chr13:28592641 FLT3 p.D835 T 0 1 0 344 0 0 0 371 0 0 0 344
chr13:28592642 FLT3 p.D835 C 0 353 0 0 0 358 0 0 0 332 0 0
chr13:28592644 FLT3 p.R834 C 0 359 0 0 0 317 1 0 0 324 0 1
chr13:28592653 FLT3 p.G831 C 0 364 0 0 0 377 0 0 0 356 0 0
chr13:28602329 FLT3 p.A680 G 0 0 248 0 1 0 271 0 0 0 154 1
chr13:28608260 FLT3 p.Y599 T 0 0 0 241 0 0 0 380 1 0 0 282
chr13:28608281 FLT3 p.V592 A 271 0 0 0 407 0 0 0 283 1 0 0
chr13:28608341 FLT3 p.Y572 T 0 0 0 278 0 0 0 449 0 0 0 225
chr13:28610138 FLT3 p.S451 G 0 0 265 0 0 0 322 0 0 0 294 2
chr13:48919244 RB1 p.E137 G 0 0 526 0 0 0 423 0 0 0 456 2
chr13:48923148 RB1 p.L199 T 0 0 0 325 0 0 0 250 0 2 0 287
chr13:48941648 RB1 p.R320 C 0 443 0 0 1 545 0 0 1 592 0 0
chr13:48942685 RB1 p.R358 C 0 341 0 0 0 477 0 0 0 398 0 0
chr13:48953760 RB1 p.R455 C 1 259 0 0 1 300 0 0 0 243 0 0
chr13:48955538 RB1 p.R552 C 1 378 0 0 2 322 0 0 2 239 0 0
chr13:48955550 RB1 p.R556 C 1 361 0 0 0 319 0 0 1 248 0 0
chr13:49027168 RB1 p.R579 C 0 443 0 1 1 478 0 0 2 502 0 0
chr13:49033844 RB1 p.R661 C 0 425 0 0 0 485 0 0 1 408 0 0
chr13:49033916 RB1 p.Q685 C 0 463 0 0 2 555 0 0 0 423 0 0
chr13:49037877 RB1 p.C706 G 2 0 458 0 0 0 420 1 0 1 428 0
chr13:49037903 RB1 p.K715 A 469 0 0 0 517 0 0 0 422 0 0 0
chr13:49039164 RB1 p.E748 G 0 0 187 2 0 0 214 2 0 0 213 1
chr13:49039183 RB1 p.V754 T 0 0 1 238 0 0 0 376 0 0 0 357
chr14:105241444 AKT1 p.K179 T 0 0 0 142 0 0 0 201 0 0 0 198
chr14:105241463 AKT1 p.G173 C 0 200 0 0 0 241 0 0 0 371 0 0
chr14:105246455 AKT1 p.E49 C 0 179 0 0 0 189 0 0 0 254 0 0
chr14:105246497 AKT1 p.F35 A 183 0 0 0 223 0 0 0 350 3 0 0
chr14:105246551 AKT1 p.E17 C 0 135 0 0 0 148 0 0 3 253 0 0
chr15:66727441 MAP2K1 p.F53 T 0 0 1 565 2 1 1 760 0 0 2 584
chr15:66727442 MAP2K1 p.F53 T 1 0 0 563 0 0 0 800 0 0 1 624
chr15:66727443 MAP2K1 p.F53 T 0 0 0 589 0 1 0 800 1 0 1 664
chr15:66727450 MAP2K1 p.Q56 C 0 605 0 0 1 716 0 0 2 612 0 0
chr15:66727451 MAP2K1 p.Q56 A 599 0 0 0 802 0 0 0 629 0 0 0
chr15:66727452 MAP2K1 p.Q56 G 0 1 616 0 0 0 759 1 0 0 645 0
chr15:66727453 MAP2K1 p.K57 A 567 2 0 0 728 1 0 0 584 7 0 0
chr15:66727454 MAP2K1 p.K57 A 569 0 0 0 749 3 0 0 601 3 0 0
chr15:66727455 MAP2K1 p.K57 G 0 0 615 0 2 0 753 1 0 0 660 0
chr15:66727483 MAP2K1 p.D67 G 0 0 588 0 0 0 718 1 0 0 593 0
chr15:66727484 MAP2K1 p.D67 A 515 2 0 0 715 1 0 0 554 0 0 0
chr15:66727485 MAP2K1 p.D67 C 0 566 0 0 0 731 0 0 1 565 0 0
chr15:66729087 MAP2K1 p.I99 A 591 2 0 0 797 1 0 0 769 0 2 0
chr15:66729088 MAP2K1 p.I99 T 0 0 1 604 1 0 0 798 2 1 0 753
chr15:66729089 MAP2K1 p.I99 T 0 0 0 614 0 0 1 799 0 0 0 783
chr15:66729102 MAP2K1 p.K104 A 563 0 1 0 803 0 0 0 820 0 0 0
chr15:66729103 MAP2K1 p.K104 A 553 0 0 2 759 1 0 0 758 3 0 0
chr15:66729104 MAP2K1 p.K104 A 516 1 0 0 671 1 0 0 732 5 0 0
chr15:66729123 MAP2K1 p.I111 A 588 0 0 0 771 0 0 0 813 1 2 0
chr15:66729124 MAP2K1 p.I111 T 0 0 0 616 0 0 1 779 0 0 1 842
chr15:66729125 MAP2K1 p.I111 C 0 645 0 0 1 796 0 0 1 852 0 0
chr15:66729135 MAP2K1 p.L115 C 0 687 0 0 0 810 0 0 1 802 0 1
chr15:66729136 MAP2K1 p.L115 T 0 0 0 655 0 0 0 831 0 0 1 794
chr15:66729137 MAP2K1 p.L115 G 3 0 695 0 0 0 828 2 0 0 810 0
chr15:66729147 MAP2K1 p.H119 C 0 709 0 0 0 859 0 0 0 780 1 0
chr15:66729148 MAP2K1 p.H119 A 696 0 0 0 930 0 0 0 831 0 0 0
chr15:66729149 MAP2K1 p.H119 T 0 0 0 694 0 0 0 923 0 0 0 800
chr15:66729150 MAP2K1 p.E120 G 0 0 730 0 0 0 903 0 0 0 772 0
chr15:66729151 MAP2K1 p.E120 A 746 0 0 0 941 0 2 0 798 0 0 0
chr15:66729152 MAP2K1 p.E120 G 0 0 726 2 0 0 921 0 0 0 828 2
chr15:66729153 MAP2K1 p.C121 T 0 0 0 621 0 0 1 846 0 0 2 681
chr15:66729154 MAP2K1 p.C121 G 0 0 722 1 0 0 888 0 0 0 783 1
chr15:66729155 MAP2K1 p.C121 C 2 700 0 0 0 876 0 0 2 742 0 0
chr15:66729162 MAP2K1 p.P124 C 1 706 0 0 0 875 0 0 0 731 0 0
chr15:66729163 MAP2K1 p.P124 C 0 685 0 0 0 801 0 1 3 717 0 0
chr15:66729164 MAP2K1 p.P124 G 0 0 722 1 0 0 848 2 0 0 757 1
chr15:66729174 MAP2K1 p.G128 G 0 0 664 0 0 0 820 0 0 0 631 0
chr15:66729175 MAP2K1 p.G128 G 0 0 706 0 0 0 833 4 0 0 639 2
chr15:66729176 MAP2K1 p.G128 C 2 667 0 0 8 834 0 0 1 659 0 0
chr15:66729177 MAP2K1 p.F129 T 0 0 2 614 0 0 2 796 0 0 1 586
chr15:66729178 MAP2K1 p.F129 T 1 0 3 581 0 0 1 763 0 0 4 565
chr15:66729179 MAP2K1 p.F129 C 0 677 0 0 0 891 0 0 2 680 0 0
chr15:66729189 MAP2K1 p.F133 T 0 0 2 540 0 0 7 750 0 0 2 541
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chr15:66729190 MAP2K1 p.F133 T 0 0 3 585 0 0 4 796 0 0 4 530
chr15:66729191 MAP2K1 p.F133 C 2 657 0 0 4 871 0 0 2 661 0 0
chr15:66774155 MAP2K1 p.V211 G 0 0 612 0 0 0 623 2 0 1 742 1
chr15:66774156 MAP2K1 p.V211 T 0 0 2 464 0 0 1 501 0 0 10 546
chr15:66774157 MAP2K1 p.V211 C 0 586 0 0 3 633 0 0 2 721 0 0
chr15:66774167 MAP2K1 p.L215 C 0 568 0 0 2 601 1 0 2 734 0 0
chr15:66774168 MAP2K1 p.L215 T 0 0 1 506 0 0 1 571 0 0 3 649
chr15:66774169 MAP2K1 p.L215 C 1 559 0 0 1 587 0 0 0 656 0 0
chr15:66781568 MAP2K1 p.P326 C 0 466 0 0 0 570 0 0 0 496 0 0
chr15:66781569 MAP2K1 p.P326 C 0 414 0 0 0 545 0 0 2 460 0 0
chr15:66781570 MAP2K1 p.P326 C 0 428 0 0 0 530 1 0 0 453 0 0
chr15:66781574 MAP2K1 p.G328 G 0 0 454 2 0 0 554 2 0 0 517 0
chr15:66781575 MAP2K1 p.G328 G 0 0 484 1 1 0 588 0 0 0 528 0
chr15:66781576 MAP2K1 p.G328 A 472 0 0 0 619 1 0 0 541 0 0 0
chr15:66782873 MAP2K1 p.E368 G 0 0 497 1 0 0 651 0 0 0 608 2
chr15:66782874 MAP2K1 p.E368 A 459 0 0 0 684 0 0 0 615 1 0 1
chr15:66782875 MAP2K1 p.E368 A 449 0 0 2 661 0 0 0 601 0 0 0
chr15:90631837 IDH2 p.R172 C 1 505 0 0 0 531 0 0 1 732 0 0
chr15:90631838 IDH2 p.R172 C 0 509 0 0 1 522 0 0 3 744 0 0
chr15:90631839 IDH2 p.R172 T 0 0 0 483 0 0 0 514 0 0 4 705
chr15:90631841 IDH2 p.G171 C 0 495 0 0 0 518 0 0 0 739 0 0
chr15:90631881 IDH2 p.P158 G 0 0 460 1 0 0 494 2 1 0 687 0
chr15:90631934 IDH2 p.R140 C 0 385 0 0 2 442 0 0 2 615 0 0
chr15:90631935 IDH2 p.R140 G 0 0 394 0 0 0 452 0 0 0 649 1
chr15:90631938 IDH2 p.I139 T 0 0 0 363 0 0 1 503 0 0 1 675
chr16:68846086 CDH1 p.E353 G 0 0 725 0 0 0 795 0 0 0 602 0
chr16:68846137 CDH1 p.D370 G 0 0 674 0 0 0 747 1 0 0 625 2
chr16:68847282 CDH1 p.D402 G 1 0 436 2 0 0 509 1 0 0 423 1
chr17:29556931 NF1 p.E977 G 0 0 586 0 0 0 621 0 0 0 643 0
chr17:29556932 NF1 p.E977 A 541 2 0 0 602 1 0 0 594 2 0 0
chr17:29556933 NF1 p.E977 A 572 0 0 0 645 0 0 0 616 2 0 0
chr17:37872775 ERBB2 p.R522 A 178 1 0 0 121 0 0 0 250 0 0 0
chr17:37872776 ERBB2 p.R522 G 0 0 199 0 0 0 136 0 0 0 262 0
chr17:37872777 ERBB2 p.R522 G 0 0 188 0 0 0 139 0 0 0 258 0
chr17:37880219 ERBB2 p.L755 T 0 0 0 125 0 0 1 175 0 0 0 185
chr17:37880220 ERBB2 p.L755 T 0 0 0 129 0 0 1 173 0 0 1 213
chr17:37880257 ERBB2 p.I767 C 0 101 0 0 0 168 0 0 0 161 0 0
chr17:37880261 ERBB2 p.D769 G 0 0 96 0 0 0 143 2 0 0 157 0
chr17:37880997 ERBB2 p.G776 G 1 0 160 0 0 0 182 0 0 0 151 0
chr17:37880998 ERBB2 p.G776 G 0 0 172 0 0 0 178 0 0 0 156 1
chr17:37881000 ERBB2 p.V777 G 0 0 174 0 0 0 182 0 0 0 165 0
chr17:37881001 ERBB2 p.V777 T 0 0 1 137 0 0 0 159 0 0 0 123
chr17:37881332 ERBB2 p.V842 G 0 0 181 0 0 0 215 0 0 0 222 0
chr17:37881440 ERBB2 p.H878 C 0 176 0 0 2 203 0 0 5 182 0 0
chr17:7573931 TP53 p.S366 A 255 0 0 0 176 0 0 0 201 0 0 1
chr17:7573961 TP53 p.G356 C 0 304 0 0 0 243 0 0 0 257 0 0
chr17:7573966 TP53 p.Q354 T 0 0 0 301 0 0 0 241 0 0 0 231
chr17:7573982 TP53 p.E349 C 1 326 0 0 1 266 0 0 0 276 0 0
chr17:7573983 TP53 p.L348 C 0 326 0 0 0 276 0 0 0 267 0 0
chr17:7573984 TP53 p.L348 A 299 1 0 1 266 0 0 0 259 2 0 0
chr17:7573996 TP53 p.L344 A 303 0 0 0 283 0 0 0 262 0 0 0
chr17:7574000 TP53 p.E343 C 0 321 0 0 0 283 0 0 0 280 0 0
chr17:7574002 TP53 p.R342 C 0 303 0 0 2 276 0 0 1 289 0 0
chr17:7574003 TP53 p.R342 G 0 0 285 0 0 0 253 0 0 0 272 0
chr17:7574012 TP53 p.E339 C 0 281 0 0 1 283 0 0 0 270 0 0
chr17:7574017 TP53 p.R337 C 0 278 0 0 1 257 0 0 0 253 0 0
chr17:7574018 TP53 p.R337 G 0 0 280 0 0 1 270 0 0 0 268 0
chr17:7574021 TP53 p.E336 C 0 271 0 0 0 285 0 0 0 268 0 0
chr17:7574026 TP53 p.G334 C 0 272 0 0 1 260 0 0 0 264 0 0
chr17:7577022 TP53 p.R306 G 0 0 535 2 0 0 477 1 0 0 524 2
chr17:7577023 TP53 p.K305 C 0 530 0 0 0 478 0 0 1 553 0 0
chr17:7577024 TP53 p.K305 T 0 0 0 508 0 0 0 484 0 0 0 511
chr17:7577025 TP53 p.K305 T 3 0 0 504 0 0 0 518 0 0 3 536
chr17:7577027 TP53 p.T304 G 0 1 532 0 0 0 500 0 0 0 565 0
chr17:7577028 TP53 p.T304 T 1 0 0 492 0 0 0 495 0 0 2 499
chr17:7577030 TP53 p.S303 C 1 536 0 0 1 501 1 0 1 586 0 0
chr17:7577031 TP53 p.S303 T 0 0 0 480 2 0 0 487 0 0 1 510
chr17:7577032 TP53 p.G302 C 0 534 0 1 0 495 1 0 1 559 0 1
chr17:7577033 TP53 p.G302 C 0 531 0 0 0 477 0 0 1 542 0 0
chr17:7577035 TP53 p.P301 T 0 0 1 532 0 0 0 506 1 0 1 536
chr17:7577037 TP53 p.P301 G 0 0 529 0 0 1 474 1 0 0 529 0
chr17:7577039 TP53 p.P300 G 0 0 528 1 0 0 501 2 0 0 549 0
chr17:7577040 TP53 p.P300 G 0 0 540 0 0 0 528 0 0 0 545 3
chr17:7577045 TP53 p.E298 T 0 0 0 498 0 0 0 494 0 0 0 481
chr17:7577046 TP53 p.E298 C 0 561 0 0 0 528 1 0 1 536 0 0
chr17:7577049 TP53 p.H297 G 0 0 538 1 0 0 524 0 0 0 489 0
chr17:7577050 TP53 p.H296 G 0 0 569 0 0 0 541 0 0 0 538 0
chr17:7577051 TP53 p.H296 T 0 0 1 499 0 0 3 494 0 0 1 438
chr17:7577052 TP53 p.H296 G 0 0 572 0 1 0 538 1 0 0 554 0
chr17:7577053 TP53 p.P295 A 528 0 0 0 495 2 0 0 494 1 0 0
chr17:7577054 TP53 p.P295 G 0 0 572 1 0 0 522 0 0 0 541 0
chr17:7577055 TP53 p.P295 G 0 0 578 0 1 0 535 0 0 0 539 0
chr17:7577056 TP53 p.E294 C 0 586 0 0 0 537 1 0 0 536 0 0
chr17:7577057 TP53 p.E294 T 0 0 1 536 2 0 0 507 0 0 3 464
chr17:7577058 TP53 p.E294 C 0 579 0 0 0 534 0 0 0 503 0 0
chr17:7577059 TP53 p.G293 C 0 558 0 0 2 491 0 0 1 479 0 0
chr17:7577061 TP53 p.G293 C 1 591 0 0 0 505 0 0 2 506 0 0
chr17:7577062 TP53 p.K292 T 1 0 0 563 0 0 2 499 0 0 4 479
chr17:7577063 TP53 p.K292 T 0 0 2 548 0 0 0 550 0 0 3 497
chr17:7577064 TP53 p.K292 T 2 0 1 574 0 0 0 559 0 0 2 528
chr17:7577065 TP53 p.K291 C 0 607 0 0 0 559 0 0 2 540 0 0
chr17:7577066 TP53 p.K291 T 0 0 0 589 0 0 0 604 1 0 1 527
chr17:7577067 TP53 p.K291 T 0 1 0 573 0 0 3 589 0 0 0 495
chr17:7577069 TP53 p.R290 C 0 592 0 0 0 497 0 0 0 502 0 0
chr17:7577070 TP53 p.R290 G 0 0 586 0 1 0 506 1 0 0 506 0
chr17:7577071 TP53 p.L289 G 0 0 601 0 0 0 521 0 0 0 516 0
chr17:7577072 TP53 p.L289 A 595 0 0 0 588 0 0 0 530 1 0 0
chr17:7577073 TP53 p.L289 G 0 1 608 0 0 0 582 0 0 0 529 1
chr17:7577075 TP53 p.N288 T 0 0 0 540 0 0 0 534 0 0 0 457
chr17:7577076 TP53 p.N288 T 1 0 0 565 0 2 1 533 0 0 3 481
chr17:7577077 TP53 p.E287 C 0 589 0 0 0 536 0 0 2 521 0 0
chr17:7577078 TP53 p.E287 T 0 0 1 562 0 0 0 539 2 0 1 525
chr17:7577079 TP53 p.E287 C 0 585 0 0 0 543 0 0 1 541 0 0
chr17:7577080 TP53 p.E286 T 0 0 1 532 0 1 0 558 0 0 1 525
chr17:7577081 TP53 p.E286 T 0 0 0 568 0 0 0 579 0 0 0 549
chr17:7577082 TP53 p.E286 C 3 578 0 0 2 526 0 0 1 515 0 0
chr17:7577083 TP53 p.E285 C 0 555 0 0 1 513 0 0 1 539 0 0
chr17:7577084 TP53 p.E285 T 0 0 0 555 0 0 0 567 0 0 2 527
chr17:7577085 TP53 p.E285 C 0 592 0 0 2 561 0 0 0 528 0 0
chr17:7577086 TP53 p.T284 T 0 0 0 550 0 0 2 578 0 0 0 520
chr17:7577088 TP53 p.T284 T 1 0 1 523 0 0 0 540 1 0 0 494
chr17:7577089 TP53 p.R283 G 0 0 551 0 0 0 527 0 0 0 537 0
chr17:7577090 TP53 p.R283 C 3 531 0 0 2 486 0 0 0 535 0 1
chr17:7577091 TP53 p.R283 G 2 0 543 2 0 0 499 1 0 0 528 1
chr17:7577092 TP53 p.R282 C 0 564 0 0 0 484 0 0 0 533 1 0
chr17:7577093 TP53 p.R282 C 0 565 0 0 0 464 0 1 1 525 0 0
chr17:7577094 TP53 p.R282 G 0 0 523 2 0 0 476 1 0 0 498 1
chr17:7577095 TP53 p.D281 G 0 0 529 0 0 0 485 1 0 0 532 0
chr17:7577096 TP53 p.D281 T 0 0 2 440 0 0 1 418 1 0 7 401
chr17:7577097 TP53 p.D281 C 0 556 0 0 0 499 0 0 1 531 0 0
chr17:7577098 TP53 p.R280 T 0 0 1 506 0 0 0 483 1 0 2 507
chr17:7577099 TP53 p.R280 C 0 549 0 0 1 503 0 0 0 551 0 1
chr17:7577100 TP53 p.R280 T 0 0 1 528 0 0 0 538 0 0 0 563
chr17:7577101 TP53 p.G279 C 0 529 0 0 1 507 1 0 0 560 0 0
chr17:7577102 TP53 p.G279 C 1 510 0 0 1 466 0 0 1 532 0 0
chr17:7577103 TP53 p.G279 C 0 515 0 0 0 465 0 0 0 513 0 1
chr17:7577105 TP53 p.P278 G 0 0 485 0 0 0 458 0 0 0 507 1
chr17:7577106 TP53 p.P278 G 0 0 510 1 0 0 490 0 0 0 529 0
chr17:7577107 TP53 p.C277 A 458 2 0 0 448 0 0 0 502 0 0 0
chr17:7577108 TP53 p.C277 C 1 503 0 0 1 481 0 0 1 519 0 0
chr17:7577109 TP53 p.C277 A 474 0 0 0 476 0 0 0 480 3 0 0
chr17:7577111 TP53 p.A276 G 0 0 479 2 0 0 477 0 0 0 491 1
chr17:7577112 TP53 p.A276 C 0 513 0 0 1 519 0 0 2 520 0 0
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chr17:7577113 TP53 p.C275 A 448 0 0 0 465 3 0 0 456 1 0 1
chr17:7577114 TP53 p.C275 C 1 486 0 0 0 493 0 0 0 521 0 0
chr17:7577115 TP53 p.C275 A 454 0 0 0 461 0 0 0 497 0 0 0
chr17:7577116 TP53 p.V274 A 441 0 0 0 481 0 0 0 473 0 0 0
chr17:7577117 TP53 p.V274 A 436 0 0 0 450 1 0 0 479 3 0 1
chr17:7577118 TP53 p.V274 C 1 485 0 0 0 479 0 0 1 500 0 0
chr17:7577120 TP53 p.R273 C 4 464 0 0 1 444 0 0 2 491 0 0
chr17:7577121 TP53 p.R273 G 1 0 445 0 0 0 425 1 0 0 454 1
chr17:7577123 TP53 p.V272 A 386 0 0 1 415 1 1 0 398 0 0 0
chr17:7577124 TP53 p.V272 C 0 452 2 0 0 436 0 0 0 495 0 0
chr17:7577125 TP53 p.E271 C 0 461 0 0 2 452 0 0 0 464 0 0
chr17:7577126 TP53 p.E271 T 0 0 0 434 0 0 1 442 0 0 0 472
chr17:7577127 TP53 p.E271 C 0 459 0 0 1 438 0 0 1 468 0 0
chr17:7577128 TP53 p.F270 A 442 0 0 0 451 0 0 0 459 2 0 0
chr17:7577129 TP53 p.F270 A 420 1 0 1 402 0 0 0 460 1 0 0
chr17:7577130 TP53 p.F270 A 434 1 0 0 388 0 0 0 470 2 0 0
chr17:7577131 TP53 p.S269 G 0 0 470 0 0 0 426 0 0 0 497 1
chr17:7577132 TP53 p.S269 C 0 454 0 0 1 433 0 0 0 489 0 0
chr17:7577133 TP53 p.S269 T 0 0 1 436 0 0 1 412 0 0 0 457
chr17:7577134 TP53 p.N268 G 0 0 440 0 0 0 415 0 0 0 452 1
chr17:7577136 TP53 p.N268 T 1 0 0 401 0 0 1 410 0 0 1 452
chr17:7577137 TP53 p.R267 C 0 445 1 0 1 394 0 0 2 456 0 0
chr17:7577138 TP53 p.R267 C 1 434 0 0 0 375 0 0 2 429 0 0
chr17:7577139 TP53 p.R267 G 0 0 452 0 0 0 392 0 0 0 462 1
chr17:7577141 TP53 p.G266 C 0 447 0 0 2 421 0 0 1 458 0 0
chr17:7577142 TP53 p.G266 C 0 418 0 0 0 403 0 0 0 446 0 0
chr17:7577144 TP53 p.L265 A 424 0 0 0 447 0 0 0 444 1 0 0
chr17:7577145 TP53 p.L265 G 0 0 444 0 0 0 423 1 0 0 460 0
chr17:7577515 TP53 p.T256 T 0 0 0 306 0 0 0 338 0 0 1 365
chr17:7577517 TP53 p.I255 A 356 1 0 0 410 0 0 0 414 0 0 2
chr17:7577518 TP53 p.I255 T 0 0 0 334 0 0 2 363 0 0 2 397
chr17:7577520 TP53 p.I254 A 356 0 0 0 397 0 0 0 408 2 0 0
chr17:7577521 TP53 p.I254 T 0 0 1 341 0 0 2 359 0 0 1 389
chr17:7577522 TP53 p.T253 G 0 0 372 1 0 0 372 0 0 0 408 0
chr17:7577523 TP53 p.T253 G 0 0 381 0 0 0 388 0 0 0 428 0
chr17:7577524 TP53 p.T253 T 0 0 1 303 0 0 1 340 0 0 2 365
chr17:7577526 TP53 p.L252 A 370 0 0 0 389 0 0 0 427 3 0 0
chr17:7577527 TP53 p.L252 G 1 0 406 1 0 0 394 0 0 1 445 1
chr17:7577528 TP53 p.I251 G 0 0 396 0 0 0 388 0 0 0 450 2
chr17:7577529 TP53 p.I251 A 370 1 0 0 377 0 0 0 434 1 0 1
chr17:7577530 TP53 p.I251 T 0 0 0 333 0 0 1 344 0 0 2 394
chr17:7577531 TP53 p.P250 G 0 0 376 0 0 0 388 1 1 1 422 0
chr17:7577532 TP53 p.P250 G 0 1 382 0 0 1 393 1 0 0 440 0
chr17:7577533 TP53 p.P250 G 0 0 409 0 0 0 400 2 0 0 454 5
chr17:7577534 TP53 p.R249 C 0 376 0 0 0 412 0 0 1 458 1 0
chr17:7577535 TP53 p.R249 C 0 377 0 0 0 380 0 0 0 429 0 0
chr17:7577536 TP53 p.R249 T 0 0 2 349 0 0 1 370 0 0 2 406
chr17:7577537 TP53 p.R248 C 0 367 0 0 0 386 0 0 0 436 0 0
chr17:7577538 TP53 p.R248 C 0 371 0 0 3 380 0 0 0 442 0 0
chr17:7577539 TP53 p.R248 G 0 0 400 1 0 0 368 0 0 0 457 2
chr17:7577540 TP53 p.N247 G 0 0 403 0 0 0 405 3 0 0 487 1
chr17:7577541 TP53 p.N247 T 0 0 0 312 0 0 1 332 0 2 4 357
chr17:7577542 TP53 p.N247 T 0 0 0 325 0 0 0 364 0 0 3 445
chr17:7577543 TP53 p.M246 C 0 383 0 0 0 401 0 0 2 455 0 0
chr17:7577544 TP53 p.M246 A 366 0 0 1 371 1 0 0 424 1 0 0
chr17:7577545 TP53 p.M246 T 0 0 0 381 0 0 0 407 0 0 1 471
chr17:7577546 TP53 p.G245 G 0 0 410 0 0 0 427 1 2 0 489 1
chr17:7577547 TP53 p.G245 C 1 377 0 0 1 394 0 0 0 452 0 0
chr17:7577548 TP53 p.G245 C 1 369 0 0 4 387 0 1 0 471 0 0
chr17:7577549 TP53 p.G244 G 0 0 383 1 0 0 389 0 0 0 463 2
chr17:7577550 TP53 p.G244 C 0 392 0 0 1 397 0 0 1 460 0 0
chr17:7577551 TP53 p.G244 C 0 349 0 0 0 387 0 0 0 425 0 0
chr17:7577552 TP53 p.M243 C 0 359 0 0 0 371 0 0 1 445 0 0
chr17:7577553 TP53 p.M243 A 341 0 0 1 369 0 0 0 431 0 0 0
chr17:7577554 TP53 p.M243 T 0 0 1 347 0 0 0 364 1 0 0 444
chr17:7577555 TP53 p.C242 G 0 0 380 0 0 0 391 0 0 0 456 0
chr17:7577556 TP53 p.C242 C 0 368 0 1 0 376 0 1 0 459 0 0
chr17:7577557 TP53 p.C242 A 364 0 0 0 400 0 0 0 458 0 0 0
chr17:7577558 TP53 p.S241 G 0 0 397 0 0 0 386 0 2 0 465 1
chr17:7577559 TP53 p.S241 G 0 0 376 1 0 0 392 0 0 0 476 1
chr17:7577560 TP53 p.S241 A 358 1 0 0 398 0 0 0 437 3 0 0
chr17:7577561 TP53 p.S240 A 334 0 1 0 373 2 0 0 399 1 0 0
chr17:7577562 TP53 p.S240 C 0 371 0 0 0 406 0 0 1 495 0 0
chr17:7577563 TP53 p.S240 T 2 0 1 365 0 0 0 406 0 0 0 479
chr17:7577564 TP53 p.N239 G 0 0 382 0 0 0 408 0 0 0 496 0
chr17:7577565 TP53 p.N239 T 0 0 0 355 0 0 1 398 0 0 1 453
chr17:7577566 TP53 p.N239 T 0 0 0 359 0 0 1 420 0 0 0 498
chr17:7577567 TP53 p.C238 A 356 0 0 0 412 0 0 0 479 1 0 2
chr17:7577568 TP53 p.C238 C 0 351 0 0 0 384 0 0 3 471 0 1
chr17:7577569 TP53 p.C238 A 343 0 0 1 385 0 0 0 466 0 1 0
chr17:7577570 TP53 p.M237 C 0 347 0 0 0 359 0 0 2 467 0 0
chr17:7577571 TP53 p.M237 A 345 0 0 1 402 0 0 0 480 2 0 0
chr17:7577572 TP53 p.M237 T 0 0 0 357 0 0 1 413 0 0 0 448
chr17:7577573 TP53 p.Y236 G 0 0 374 0 0 1 393 0 0 0 481 0
chr17:7577574 TP53 p.Y236 T 1 0 0 347 0 0 0 392 0 0 3 478
chr17:7577575 TP53 p.Y236 A 347 0 0 0 403 0 0 0 472 0 0 0
chr17:7577577 TP53 p.N235 T 0 0 0 319 0 0 0 352 0 1 3 438
chr17:7577578 TP53 p.N235 T 0 0 1 321 0 0 1 375 0 0 2 463
chr17:7577579 TP53 p.Y234 G 0 0 364 0 0 0 411 1 0 0 492 0
chr17:7577580 TP53 p.Y234 T 0 2 3 309 0 0 0 398 0 0 1 449
chr17:7577581 TP53 p.Y234 A 335 0 0 0 391 0 0 0 458 0 0 0
chr17:7577582 TP53 p.H233 G 0 0 380 0 0 0 418 2 0 0 498 0
chr17:7577583 TP53 p.H233 T 0 0 0 289 0 0 0 367 2 0 2 409
chr17:7577584 TP53 p.H233 G 0 0 354 0 0 0 403 0 0 0 450 1
chr17:7577586 TP53 p.I232 A 316 0 0 0 379 0 0 0 439 1 0 0
chr17:7577587 TP53 p.I232 T 0 0 1 290 0 0 1 351 0 0 0 421
chr17:7577588 TP53 p.T231 G 0 0 339 0 0 0 379 0 0 0 433 2
chr17:7577589 TP53 p.T231 G 0 0 338 0 0 0 396 0 0 0 448 0
chr17:7577590 TP53 p.T231 T 0 0 0 282 0 0 2 325 0 2 1 396
chr17:7577592 TP53 p.T230 G 0 0 335 1 0 0 397 1 0 0 460 0
chr17:7577593 TP53 p.T230 T 1 0 1 273 0 0 1 336 0 0 2 401
chr17:7577594 TP53 p.C229 A 286 0 0 1 350 0 0 0 422 1 0 0
chr17:7577595 TP53 p.C229 C 0 303 0 0 0 349 1 0 3 431 0 0
chr17:7577596 TP53 p.C229 A 297 0 0 0 355 0 0 0 424 1 0 0
chr17:7577597 TP53 p.D228 G 0 0 341 0 0 0 373 2 0 0 450 0
chr17:7577598 TP53 p.D228 T 0 0 2 286 0 0 1 339 0 0 1 392
chr17:7577599 TP53 p.D228 C 0 293 0 0 0 348 0 0 1 433 0 0
chr17:7577601 TP53 p.S227 G 0 0 315 2 0 0 373 0 0 0 433 1
chr17:7577603 TP53 p.G226 G 0 0 308 1 0 0 350 0 0 0 416 0
chr17:7577604 TP53 p.G226 C 0 302 0 0 0 337 0 0 2 397 0 2
chr17:7577605 TP53 p.G226 C 1 304 0 0 0 355 0 0 0 398 0 0
chr17:7578187 TP53 p.E221 T 0 0 1 399 0 1 2 494 0 1 4 442
chr17:7578188 TP53 p.E221 C 0 444 0 0 1 506 0 0 0 521 0 0
chr17:7578189 TP53 p.Y220 A 441 1 0 0 507 0 0 0 496 0 0 0
chr17:7578190 TP53 p.Y220 T 1 0 1 416 1 0 1 537 0 0 4 485
chr17:7578191 TP53 p.Y220 A 419 0 0 0 531 1 0 0 476 1 0 0
chr17:7578192 TP53 p.P219 G 1 0 417 1 0 0 488 0 0 0 455 1
chr17:7578193 TP53 p.P219 G 0 0 415 0 0 0 481 2 0 0 494 0
chr17:7578194 TP53 p.P219 G 0 0 426 1 0 0 522 0 0 0 486 2
chr17:7578196 TP53 p.V218 A 362 0 0 0 472 3 0 0 396 0 0 0
chr17:7578197 TP53 p.V218 C 2 473 0 0 2 533 0 0 0 549 0 0
chr17:7578199 TP53 p.V217 A 387 1 0 0 466 2 0 0 442 2 0 0
chr17:7578200 TP53 p.V217 C 0 497 0 0 2 551 0 0 1 581 0 0
chr17:7578202 TP53 p.V216 A 443 0 0 0 479 0 0 0 508 0 0 0
chr17:7578203 TP53 p.V216 C 1 485 0 0 1 538 0 0 1 565 0 0
chr17:7578204 TP53 p.S215 A 450 0 0 0 520 2 0 1 533 3 0 0
chr17:7578205 TP53 p.S215 C 0 503 0 0 0 575 0 0 0 606 0 0
chr17:7578206 TP53 p.S215 T 0 0 1 445 1 0 0 559 0 0 1 518
chr17:7578207 TP53 p.H214 A 467 1 0 0 596 1 0 0 543 0 0 0
chr17:7578208 TP53 p.H214 T 0 0 0 501 0 0 0 594 1 0 0 540
chr17:7578209 TP53 p.H214 G 0 0 473 0 0 0 535 1 0 0 530 0
chr17:7578211 TP53 p.R213 C 0 525 0 0 0 551 0 1 0 519 0 0
chr17:7578212 TP53 p.R213 G 0 0 507 0 0 0 554 0 0 0 548 0
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chr17:7578213 TP53 p.F212 A 497 0 0 0 610 0 0 0 563 0 0 0
chr17:7578214 TP53 p.F212 A 492 0 0 0 575 0 0 0 537 0 0 0
chr17:7578215 TP53 p.F212 A 479 0 0 0 566 0 0 0 530 0 0 0
chr17:7578216 TP53 p.T211 A 490 0 0 0 579 0 0 0 533 0 1 0
chr17:7578217 TP53 p.T211 G 0 0 491 1 0 0 557 1 0 0 541 2
chr17:7578218 TP53 p.T211 T 0 0 0 466 0 0 1 561 0 0 1 519
chr17:7578220 TP53 p.N210 T 0 0 4 420 0 0 0 521 2 0 1 494
chr17:7578223 TP53 p.R209 C 0 524 0 0 0 592 0 0 0 570 0 0
chr17:7578224 TP53 p.R209 T 1 2 0 488 1 0 1 593 0 0 1 570
chr17:7578225 TP53 p.D208 G 0 0 491 0 0 0 579 0 0 0 557 1
chr17:7578226 TP53 p.D208 T 0 0 0 457 0 0 2 549 0 0 0 519
chr17:7578227 TP53 p.D208 C 1 501 0 0 0 576 0 0 0 549 1 0
chr17:7578229 TP53 p.D207 T 0 1 0 490 0 0 0 598 0 0 0 602
chr17:7578232 TP53 p.L206 A 493 1 0 1 609 0 0 0 628 0 0 0
chr17:7578234 TP53 p.Y205 A 486 0 0 0 579 2 0 0 590 2 0 0
chr17:7578235 TP53 p.Y205 T 1 0 0 515 0 0 1 610 0 0 0 608
chr17:7578236 TP53 p.Y205 A 472 0 0 0 593 0 0 0 614 1 0 0
chr17:7578237 TP53 p.E204 C 0 536 0 0 2 596 0 0 0 639 0 0
chr17:7578238 TP53 p.E204 T 0 0 0 505 0 0 0 594 0 1 0 611
chr17:7578239 TP53 p.E204 C 0 513 0 0 3 560 0 0 1 593 0 0
chr17:7578240 TP53 p.V203 C 0 500 0 0 0 546 0 0 2 582 0 0
chr17:7578241 TP53 p.V203 A 420 1 0 0 494 1 0 1 533 1 0 1
chr17:7578242 TP53 p.V203 C 1 525 0 0 0 574 0 0 1 600 0 0
chr17:7578243 TP53 p.R202 A 425 1 0 1 515 0 0 0 528 2 0 0
chr17:7578244 TP53 p.R202 C 2 534 0 0 0 568 0 0 2 602 0 0
chr17:7578245 TP53 p.R202 G 0 0 484 1 0 0 539 5 3 0 551 1
chr17:7578246 TP53 p.L201 C 0 536 0 0 0 577 0 0 0 611 0 0
chr17:7578250 TP53 p.N200 T 1 0 0 494 0 0 0 582 1 0 2 636
chr17:7578252 TP53 p.G199 T 0 0 0 517 1 0 0 609 0 0 0 642
chr17:7578253 TP53 p.G199 C 1 529 0 0 2 588 0 0 2 646 0 0
chr17:7578254 TP53 p.G199 C 0 515 0 0 0 562 0 2 1 591 0 0
chr17:7578257 TP53 p.E198 C 0 521 0 0 0 547 0 0 1 611 0 0
chr17:7578258 TP53 p.V197 C 0 502 0 0 1 517 0 0 0 581 0 1
chr17:7578259 TP53 p.V197 A 429 2 0 0 485 2 0 0 561 2 0 0
chr17:7578260 TP53 p.V197 C 0 495 0 0 0 518 0 0 0 634 0 0
chr17:7578261 TP53 p.R196 T 0 0 0 492 0 0 0 553 0 0 0 623
chr17:7578262 TP53 p.R196 C 0 502 0 0 0 520 0 0 2 595 0 0
chr17:7578263 TP53 p.R196 G 0 0 478 1 0 0 496 0 0 0 568 1
chr17:7578264 TP53 p.I195 G 0 0 473 1 0 0 503 0 0 0 608 0
chr17:7578265 TP53 p.I195 A 476 0 0 0 568 0 0 0 659 1 0 0
chr17:7578266 TP53 p.I195 T 1 0 2 470 0 0 0 539 0 0 0 626
chr17:7578267 TP53 p.L194 A 456 0 0 0 543 0 0 0 622 0 0 0
chr17:7578268 TP53 p.L194 A 464 1 0 2 547 0 0 0 644 1 0 1
chr17:7578269 TP53 p.L194 G 0 0 483 1 0 0 528 0 0 0 651 0
chr17:7578270 TP53 p.H193 A 458 0 2 0 506 2 0 0 642 6 0 0
chr17:7578271 TP53 p.H193 T 2 0 0 449 0 0 0 531 0 1 0 651
chr17:7578272 TP53 p.H193 G 0 0 487 2 0 0 503 0 0 0 656 2
chr17:7578273 TP53 p.Q192 C 0 508 0 0 2 509 0 0 1 652 0 0
chr17:7578274 TP53 p.Q192 T 1 0 1 432 0 0 0 480 0 0 4 602
chr17:7578275 TP53 p.Q192 G 0 1 487 0 0 0 526 0 0 0 658 1
chr17:7578277 TP53 p.P191 G 1 0 484 0 0 0 499 0 0 0 674 0
chr17:7578278 TP53 p.P191 G 0 1 491 0 0 0 499 0 0 0 665 0
chr17:7578280 TP53 p.P190 G 0 0 486 0 0 0 505 0 0 0 619 0
chr17:7578281 TP53 p.P190 G 0 0 471 0 0 0 470 1 0 0 581 1
chr17:7578282 TP53 p.A189 G 0 0 491 1 0 0 486 1 0 1 632 1
chr17:7578283 TP53 p.A189 G 0 0 476 0 1 0 510 0 0 0 651 3
chr17:7578284 TP53 p.A189 C 3 483 0 0 1 507 0 0 1 654 0 0
chr17:7578289 TP53 p.G187 C 1 489 0 0 1 487 0 0 2 722 0 0
chr17:7578371 TP53 p.G187 C 0 441 0 0 2 459 0 0 0 550 0 0
chr17:7578372 TP53 p.D186 A 418 1 0 0 435 0 0 0 507 2 0 1
chr17:7578374 TP53 p.D186 C 1 465 0 0 0 482 0 0 1 587 0 0
chr17:7578375 TP53 p.S185 G 0 0 462 0 0 0 469 0 0 0 572 0
chr17:7578377 TP53 p.S185 T 0 1 0 452 0 0 0 499 0 0 0 575
chr17:7578378 TP53 p.D184 A 443 2 0 0 500 0 0 0 550 1 0 0
chr17:7578380 TP53 p.D184 C 0 457 0 0 0 485 0 0 0 585 0 0
chr17:7578382 TP53 p.S183 G 0 0 436 0 0 0 484 0 0 0 538 1
chr17:7578383 TP53 p.S183 A 411 2 1 0 456 1 0 0 468 3 0 0
chr17:7578384 TP53 p.C182 G 0 0 471 0 0 0 474 0 0 0 536 2
chr17:7578385 TP53 p.C182 C 0 468 0 0 0 498 0 0 0 566 0 0
chr17:7578386 TP53 p.C182 A 434 0 0 0 467 1 0 0 525 0 0 0
chr17:7578387 TP53 p.R181 G 0 0 470 1 0 0 469 2 0 0 557 1
chr17:7578388 TP53 p.R181 C 1 459 1 0 1 459 0 0 0 537 0 0
chr17:7578389 TP53 p.R181 G 0 0 440 0 0 0 407 0 0 0 492 0
chr17:7578390 TP53 p.E180 C 0 452 0 0 0 479 0 0 1 565 0 0
chr17:7578392 TP53 p.E180 C 2 437 0 0 0 492 0 0 0 529 0 0
chr17:7578393 TP53 p.H179 A 455 1 0 0 503 0 0 0 543 0 1 0
chr17:7578394 TP53 p.H179 T 0 0 0 438 0 0 1 504 0 0 3 546
chr17:7578395 TP53 p.H179 G 0 0 447 0 0 0 469 0 0 0 537 0
chr17:7578396 TP53 p.H178 G 0 0 454 0 0 0 479 1 0 0 527 1
chr17:7578397 TP53 p.H178 T 0 0 1 338 0 0 2 410 0 0 1 401
chr17:7578398 TP53 p.H178 G 0 0 439 0 0 0 493 1 0 0 511 0
chr17:7578399 TP53 p.P177 G 0 0 445 1 0 0 459 0 0 0 475 1
chr17:7578400 TP53 p.P177 G 0 0 431 0 0 0 443 1 0 0 465 0
chr17:7578401 TP53 p.P177 G 0 0 444 0 2 0 467 0 0 0 508 0
chr17:7578402 TP53 p.C176 G 0 0 448 0 0 0 479 1 0 0 503 0
chr17:7578403 TP53 p.C176 C 2 450 0 0 0 478 0 0 0 512 0 1
chr17:7578404 TP53 p.C176 A 406 0 0 0 459 3 0 0 425 4 0 0
chr17:7578405 TP53 p.R175 G 1 0 449 0 0 0 476 1 0 0 483 0
chr17:7578406 TP53 p.R175 C 1 457 0 0 2 463 0 0 0 478 0 0
chr17:7578407 TP53 p.R175 G 0 0 434 1 0 0 470 0 0 0 464 0
chr17:7578408 TP53 p.R174 C 0 430 0 0 0 448 0 0 0 518 0 1
chr17:7578409 TP53 p.R174 C 0 449 0 0 0 474 0 0 1 506 0 0
chr17:7578410 TP53 p.R174 T 0 0 2 369 0 0 2 431 0 0 1 420
chr17:7578411 TP53 p.V173 C 1 447 0 0 0 507 0 0 0 487 0 0
chr17:7578412 TP53 p.V173 A 417 1 0 0 465 1 0 0 415 3 0 0
chr17:7578413 TP53 p.V173 C 0 433 0 1 1 493 0 0 0 476 0 0
chr17:7578414 TP53 p.V172 A 410 1 0 0 493 0 0 0 443 2 0 1
chr17:7578415 TP53 p.V172 A 370 0 0 2 433 4 0 0 421 2 0 1
chr17:7578416 TP53 p.V172 C 0 444 0 0 0 487 0 0 0 495 1 0
chr17:7578418 TP53 p.E171 T 0 0 0 423 0 0 0 502 0 0 0 469
chr17:7578419 TP53 p.E171 C 0 425 0 0 0 490 0 0 2 467 0 0
chr17:7578420 TP53 p.T170 C 0 438 0 0 0 490 0 0 3 459 0 0
chr17:7578421 TP53 p.T170 G 0 0 438 1 0 0 486 0 0 0 483 1
chr17:7578423 TP53 p.M169 C 0 414 1 0 0 517 0 0 0 470 0 0
chr17:7578424 TP53 p.M169 A 405 0 0 0 507 1 0 0 440 3 0 0
chr17:7578425 TP53 p.M169 T 0 0 0 416 0 0 1 484 0 0 0 441
chr17:7578426 TP53 p.H168 G 0 0 418 0 0 0 476 0 0 0 463 0
chr17:7578427 TP53 p.H168 T 0 0 0 375 0 0 0 455 0 0 1 426
chr17:7578428 TP53 p.H168 G 0 0 431 0 0 0 494 0 0 0 464 0
chr17:7578429 TP53 p.Q167 C 1 434 0 0 2 464 0 0 0 465 0 0
chr17:7578430 TP53 p.Q167 T 0 0 2 376 0 0 1 441 0 0 2 390
chr17:7578431 TP53 p.Q167 G 0 0 436 0 0 0 477 0 0 0 439 0
chr17:7578433 TP53 p.S166 G 0 0 437 0 0 0 479 1 0 0 439 0
chr17:7578434 TP53 p.S166 A 363 0 0 0 445 0 0 0 384 3 0 0
chr17:7578436 TP53 p.Q165 T 0 0 1 405 0 0 0 471 0 0 1 401
chr17:7578437 TP53 p.Q165 G 0 0 411 0 0 0 475 0 0 1 443 1
chr17:7578438 TP53 p.K164 C 0 404 0 0 0 440 0 0 0 382 0 0
chr17:7578439 TP53 p.K164 T 1 0 0 349 0 0 0 407 0 1 1 368
chr17:7578440 TP53 p.K164 T 1 0 0 339 0 0 0 435 0 0 1 370
chr17:7578441 TP53 p.Y163 G 0 0 390 0 0 0 458 0 0 0 416 1
chr17:7578442 TP53 p.Y163 T 0 0 1 363 0 0 0 444 0 0 1 385
chr17:7578443 TP53 p.Y163 A 375 0 0 1 462 1 0 0 404 0 0 0
chr17:7578444 TP53 p.I162 G 0 0 406 0 0 0 467 0 0 0 424 0
chr17:7578445 TP53 p.I162 A 357 0 0 0 429 1 1 0 378 2 0 1
chr17:7578446 TP53 p.I162 T 0 0 0 363 0 0 0 392 0 0 2 364
chr17:7578447 TP53 p.A161 G 0 0 387 0 0 0 424 0 0 0 384 1
chr17:7578448 TP53 p.A161 G 0 0 368 1 0 0 439 0 0 0 379 0
chr17:7578449 TP53 p.A161 C 0 379 0 0 0 425 0 0 2 385 0 0
chr17:7578450 TP53 p.M160 C 0 341 0 0 2 407 0 0 1 360 0 0
chr17:7578451 TP53 p.M160 A 343 1 0 0 403 2 0 0 341 0 0 1
chr17:7578452 TP53 p.M160 T 1 0 1 329 0 0 0 406 0 0 0 349
chr17:7578453 TP53 p.A159 G 0 0 341 0 0 0 420 0 0 0 356 0
chr17:7578454 TP53 p.A159 G 0 0 356 1 0 0 404 0 1 0 371 0
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chr17:7578455 TP53 p.A159 C 0 362 0 0 0 402 0 0 1 361 0 0
chr17:7578456 TP53 p.R158 G 0 0 345 0 0 0 401 1 0 0 361 1
chr17:7578457 TP53 p.R158 C 0 334 0 0 0 410 0 0 0 359 0 0
chr17:7578458 TP53 p.R158 G 0 0 326 0 0 0 386 0 0 0 348 1
chr17:7578459 TP53 p.V157 G 0 0 357 0 2 0 436 0 0 0 376 0
chr17:7578460 TP53 p.V157 A 284 1 0 0 380 2 0 0 302 2 0 0
chr17:7578461 TP53 p.V157 C 0 334 0 0 1 390 0 0 0 349 0 0
chr17:7578462 TP53 p.R156 G 0 0 339 0 1 0 392 0 0 0 351 0
chr17:7578463 TP53 p.R156 C 0 326 0 0 2 383 0 0 1 320 0 0
chr17:7578464 TP53 p.R156 G 0 0 315 0 1 0 351 3 2 0 316 1
chr17:7578465 TP53 p.T155 G 0 0 326 0 0 0 377 1 0 0 327 1
chr17:7578466 TP53 p.T155 G 0 0 334 0 0 0 398 0 0 0 324 0
chr17:7578467 TP53 p.T155 T 0 0 1 230 0 0 1 305 0 0 2 219
chr17:7578468 TP53 p.G154 G 0 0 306 0 1 0 390 1 0 0 322 0
chr17:7578469 TP53 p.G154 C 1 284 0 0 1 387 0 0 0 290 0 0
chr17:7578470 TP53 p.G154 C 1 279 0 0 0 360 0 0 1 293 0 0
chr17:7578471 TP53 p.P153 G 0 0 298 0 0 0 340 0 0 0 278 0
chr17:7578472 TP53 p.P153 G 0 0 297 0 0 0 379 0 0 0 296 0
chr17:7578473 TP53 p.P153 G 0 0 294 0 0 0 369 0 0 0 297 0
chr17:7578474 TP53 p.P152 C 2 284 0 0 3 369 0 0 2 312 0 0
chr17:7578475 TP53 p.P152 G 0 0 258 0 0 0 294 2 0 0 270 0
chr17:7578476 TP53 p.P152 G 0 0 278 0 0 0 360 1 0 0 306 0
chr17:7578477 TP53 p.P151 G 0 0 282 0 0 0 351 0 0 0 305 0
chr17:7578523 TP53 p.Q136 T 1 0 0 207 0 0 0 330 0 0 0 236
chr17:7578524 TP53 p.Q136 G 0 0 228 0 0 0 321 2 0 0 241 2
chr17:7578525 TP53 p.C135 G 0 0 229 0 0 0 330 0 0 0 243 0
chr17:7578526 TP53 p.C135 C 0 230 0 0 0 332 0 0 0 266 0 0
chr17:7578527 TP53 p.C135 A 210 0 0 0 338 0 0 0 223 0 0 0
chr17:7578528 TP53 p.F134 A 204 0 0 0 354 0 0 0 246 0 0 0
chr17:7578529 TP53 p.F134 A 202 0 0 0 344 0 0 0 231 0 0 0
chr17:7578530 TP53 p.F134 A 193 0 0 0 320 0 0 0 238 0 0 0
chr17:7578531 TP53 p.M133 C 0 221 0 0 0 337 0 0 1 251 0 0
chr17:7578532 TP53 p.M133 A 205 0 0 0 337 0 0 0 260 0 0 0
chr17:7578534 TP53 p.K132 C 0 210 0 0 0 343 0 0 0 258 0 0
chr17:7578535 TP53 p.K132 T 0 0 0 206 0 0 0 347 0 0 0 264
chr17:7578536 TP53 p.K132 T 0 0 0 194 0 0 0 340 0 0 1 253
chr17:7578538 TP53 p.N131 T 0 0 1 177 0 0 1 326 0 0 0 259
chr17:7578539 TP53 p.N131 T 0 0 1 184 0 0 0 319 0 0 0 255
chr17:7578540 TP53 p.L130 G 0 0 197 0 0 0 322 0 0 0 259 0
chr17:7578541 TP53 p.L130 A 193 0 0 1 327 0 0 0 251 0 0 0
chr17:7578542 TP53 p.L130 G 0 0 206 0 0 0 318 0 0 0 244 0
chr17:7578544 TP53 p.A129 G 0 0 214 0 0 0 311 0 0 0 261 0
chr17:7578545 TP53 p.A129 C 0 203 0 0 0 303 0 0 0 249 0 0
chr17:7578547 TP53 p.P128 G 0 0 204 0 2 0 299 0 0 0 265 0
chr17:7578548 TP53 p.P128 G 0 0 201 1 0 0 307 0 0 0 243 1
chr17:7578549 TP53 p.S127 G 0 0 191 1 0 0 310 0 0 0 248 0
chr17:7578550 TP53 p.S127 G 0 1 187 0 0 0 303 0 0 0 268 0
chr17:7578551 TP53 p.S127 A 179 0 0 0 317 0 0 0 258 1 0 0
chr17:7578552 TP53 p.Y126 G 0 0 190 0 0 0 310 0 0 0 275 0
chr17:7578553 TP53 p.Y126 T 0 0 1 169 0 0 0 297 0 0 5 249
chr17:7578554 TP53 p.Y126 A 177 0 0 0 322 0 0 0 260 0 0 0
chr17:7579358 TP53 p.R110 C 0 261 2 0 0 251 1 0 1 216 0 0
chr17:7579359 TP53 p.R110 G 0 0 246 0 0 0 236 1 0 0 207 0
chr17:7579361 TP53 p.F109 A 230 0 0 0 257 0 0 0 184 1 0 0
chr17:7579365 TP53 p.G108 C 0 263 0 0 1 237 0 0 1 192 0 0
chr17:7579366 TP53 p.Y107 G 0 0 268 0 0 0 248 0 0 0 199 1
chr17:7579368 TP53 p.Y107 A 237 0 0 0 241 0 0 0 193 1 0 0
chr17:7579369 TP53 p.S106 G 0 0 267 0 0 0 253 1 0 0 214 0
chr17:7579374 TP53 p.G105 C 0 224 1 0 0 219 0 0 1 178 0 0
chr17:7579377 TP53 p.Q104 G 0 0 242 0 0 0 239 1 0 0 186 1
chr17:7579378 TP53 p.Y103 G 0 0 252 0 0 0 235 0 0 0 199 0
chr17:7579382 TP53 p.T102 G 0 0 252 0 0 0 231 2 0 0 189 1
chr17:7579385 TP53 p.K101 T 0 0 0 245 0 0 0 225 0 0 0 182
chr17:7579389 TP53 p.Q100 G 0 0 266 0 0 0 227 1 0 0 194 1
chr17:7579391 TP53 p.S99 G 0 0 254 0 0 0 213 0 0 0 185 0
chr17:7579394 TP53 p.P98 G 0 0 262 0 0 0 226 0 0 0 202 0
chr17:7579395 TP53 p.P98 G 0 0 253 1 0 0 222 1 0 0 189 1
chr17:7579400 TP53 p.S96 G 0 0 256 0 0 0 209 0 0 0 206 0
chr17:7579403 TP53 p.S95 G 0 0 250 1 0 0 225 1 0 0 208 0
chr17:7579406 TP53 p.S94 G 0 0 250 0 0 0 212 0 0 0 186 1
chr17:7579407 TP53 p.S94 A 205 1 0 0 180 2 0 0 150 1 0 0
chr17:7579414 TP53 p.W91 C 0 265 0 0 0 226 0 0 0 199 0 0
chr17:7579415 TP53 p.W91 C 0 236 0 0 0 223 0 0 0 175 0 0
chr17:7579422 TP53 p.P89 G 0 0 268 0 0 0 231 0 0 0 180 0
chr17:7579427 TP53 p.P87 G 0 0 264 0 1 0 245 1 0 0 181 0
chr17:7579434 TP53 p.P85 G 0 0 286 0 0 0 269 0 0 0 186 0
chr17:7579436 TP53 p.A84 G 0 0 256 0 0 0 238 0 0 0 187 0
chr17:7579442 TP53 p.P82 G 0 0 283 0 0 0 248 0 0 0 177 0
chr17:7579445 TP53 p.T81 G 0 0 253 0 0 0 258 0 0 0 198 0
chr17:7579454 TP53 p.A78 G 0 0 264 0 0 0 242 0 0 0 187 0
chr17:7579458 TP53 p.P77 G 1 0 278 1 0 0 249 0 0 0 197 0
chr17:7579463 TP53 p.P75 G 0 0 301 0 0 0 280 0 0 0 219 0
chr17:7579470 TP53 p.V73 C 0 216 0 0 0 222 1 0 0 177 0 0
chr17:7579472 TP53 p.R72 G 0 76 231 0 0 82 221 0 0 61 168 0
chr17:7579473 TP53 p.R72 G 0 0 320 0 0 0 325 0 0 0 237 0
chr17:7579882 TP53 p.E11 C 0 439 0 0 0 467 0 0 0 313 0 0
chr18:48575159 SMAD4 p.A118 C 0 247 0 0 0 255 0 1 0 267 1 0
chr18:48575671 SMAD4 p.S144 C 0 169 0 0 1 257 0 0 0 145 0 0
chr18:48581198 SMAD4 p.G168 G 0 0 209 0 0 0 183 0 0 0 243 0
chr18:48584560 SMAD4 p.Q245 C 1 282 0 1 0 294 0 0 1 344 0 0
chr18:48586262 SMAD4 p.Q311 C 0 258 0 0 0 255 0 0 0 197 0 0
chr18:48591826 SMAD4 p.E330 A 267 0 0 0 304 0 1 0 401 0 0 0
chr18:48591865 SMAD4 p.S343 C 0 276 0 0 0 250 0 0 0 379 0 0
chr18:48591888 SMAD4 p.D351 G 0 0 260 0 0 0 239 0 0 0 326 1
chr18:48591895 SMAD4 p.Y353 A 239 0 0 0 237 0 0 1 322 0 0 0
chr18:48591901 SMAD4 p.D355 A 225 0 0 0 230 0 0 0 297 1 0 0
chr18:48591909 SMAD4 p.G358 G 1 0 249 0 0 0 210 0 0 0 278 0
chr18:48591918 SMAD4 p.R361 C 1 240 0 0 0 210 0 0 1 235 0 0
chr18:48591919 SMAD4 p.R361 G 0 0 245 0 0 0 206 0 0 0 228 2
chr18:48593405 SMAD4 p.G386 G 0 0 235 1 0 0 249 0 0 0 330 0
chr18:48593485 SMAD4 p.Y412 C 0 289 0 0 0 304 0 0 0 273 0 0
chr18:48603032 SMAD4 p.R445 C 1 224 0 0 0 201 0 0 0 147 0 0
chr18:48604668 SMAD4 p.R497 G 0 0 242 0 0 0 247 0 0 0 222 0
chr18:48604674 SMAD4 p.C499 G 0 0 256 0 2 0 260 0 0 0 254 0
chr18:48604697 SMAD4 p.K507 A 243 0 0 0 260 0 0 0 253 0 0 0
chr18:48604721 SMAD4 p.R515 A 225 0 0 0 216 0 0 0 275 2 0 0
chr18:48604747 SMAD4 p.C523 C 0 203 0 0 0 166 0 0 1 188 0 0
chr18:48604754 SMAD4 p.E526 G 0 0 197 0 0 0 164 0 0 0 190 0
chr19:1207008 STK11 p.T32 C 0 186 0 0 1 142 0 0 4 284 0 0
chr19:1207021 STK11 p.Q37 C 0 175 0 0 0 140 0 0 1 289 0 0
chr19:1207092 STK11 p.Y60 C 0 177 0 0 0 128 0 0 0 267 0 0
chr19:1220382 STK11 p.Q159 C 0 132 0 0 0 90 0 0 0 168 0 0
chr19:1220415 STK11 p.Q170 C 0 116 0 0 0 92 0 0 0 210 0 0
chr19:1220418 STK11 p.G171 G 0 0 121 0 0 0 88 0 0 0 191 0
chr19:1220487 STK11 p.D194 G 0 0 84 0 0 0 66 0 0 0 137 0
chr19:1220488 STK11 p.D194 A 62 1 0 0 52 0 0 0 107 1 0 0
chr19:1220494 STK11 p.G196 G 0 0 79 0 0 0 63 0 0 0 141 0
chr19:1220502 STK11 p.E199 G 0 0 73 0 0 0 53 0 0 0 110 0
chr19:1221293 STK11 p.Y272 C 0 150 0 0 0 122 0 0 0 198 0 0
chr19:1221318 STK11 p.P281 C 0 105 0 0 0 102 0 0 0 114 0 0
chr19:1221319 STK11 p.P281 C 0 107 0 0 0 93 0 0 0 111 0 0
chr19:1223059 STK11 p.W332 G 0 0 125 0 0 0 58 0 0 0 102 1
chr19:1223125 STK11 p.F354 C 0 168 0 0 0 89 0 0 0 182 0 0
chr19:17945696 JAK3 p.V722 C 0 388 0 1 0 362 0 0 1 381 0 0
chr19:17948006 JAK3 p.A573 G 0 0 292 0 0 0 295 1 0 0 358 0
chr19:17948009 JAK3 p.A572 G 0 0 304 0 0 0 300 1 0 0 364 1
chr19:17954215 JAK3 p.P132 G 0 0 375 0 0 0 342 2 0 0 532 0
chr19:3118941 GNA11 p.Q209 C 0 162 0 0 0 163 0 0 0 141 0 0
chr19:3118942 GNA11 p.Q209 A 146 0 0 1 152 1 0 0 105 0 0 0
chr19:3118943 GNA11 p.Q209 G 0 0 174 0 0 0 178 0 0 0 157 0
chr1:115252204 NRAS p.A146 C 0 413 0 1 1 524 0 0 1 606 0 0
chr1:115256518 NRAS p.S65 T 0 0 0 326 0 0 0 319 0 0 4 408
chr1:115256528 NRAS p.Q61 T 1 0 0 288 0 0 0 284 0 0 0 324
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chr1:115256529 NRAS p.Q61 T 1 0 0 271 0 0 0 285 0 0 0 333
chr1:115256530 NRAS p.Q61 G 0 0 270 0 0 0 260 0 0 0 310 0
chr1:115256531 NRAS p.G60 T 0 0 0 253 0 0 0 259 0 0 0 319
chr1:115256532 NRAS p.G60 C 0 264 0 0 0 255 0 0 0 296 0 0
chr1:115258728 NRAS p.A18 T 1 0 1 404 0 0 1 524 0 2 3 652
chr1:115258729 NRAS p.A18 G 0 0 454 0 0 0 557 0 0 0 733 0
chr1:115258730 NRAS p.A18 C 1 444 0 0 0 530 0 2 1 679 0 0
chr1:115258743 NRAS p.G13 A 382 0 0 0 513 4 0 0 650 5 0 0
chr1:115258744 NRAS p.G13 C 0 467 0 0 0 577 0 0 1 749 0 0
chr1:115258745 NRAS p.G13 C 0 458 0 0 3 555 0 0 0 674 0 0
chr1:115258746 NRAS p.G12 A 381 1 0 0 521 1 0 0 607 3 0 0
chr1:115258747 NRAS p.G12 C 3 457 0 0 1 571 0 0 1 722 0 0
chr1:115258748 NRAS p.G12 C 0 477 0 0 2 560 0 0 1 712 0 0
chr1:115258751 NRAS p.A11 C 0 472 0 0 0 570 0 0 0 722 0 0
chr1:43814979 MPL p.S505 G 0 0 166 0 0 0 164 0 0 0 234 0
chr1:43814981 MPL p.A506 G 0 0 168 0 0 0 158 0 0 0 252 0
chr1:43815008 MPL p.W515 T 0 0 1 140 0 0 1 146 0 0 1 151
chr1:43815009 MPL p.W515 G 0 0 171 0 0 0 170 0 0 0 186 0
chr1:43815010 MPL p.W515 G 0 0 165 0 0 0 164 0 0 0 182 0
chr1:43815020 MPL p.A519 G 0 0 157 0 0 0 153 0 0 0 138 0
chr20:36031762 SRC p.Q531 C 0 249 0 0 1 258 0 0 0 307 0 0
chr20:57484420 GNAS p.R201 C 0 665 0 0 4 793 0 0 3 927 0 0
chr20:57484421 GNAS p.R201 G 0 0 687 0 0 1 819 3 0 1 973 0
chr20:57484595 GNAS p.Q227 C 0 687 0 0 0 768 1 0 1 979 0 0
chr20:57484596 GNAS p.Q227 A 641 2 0 0 738 0 0 0 919 5 0 0
chr20:57484597 GNAS p.Q227 G 0 0 710 0 0 0 771 0 0 1 1023 1
chr20:57484615 GNAS p.K233 G 0 0 708 0 0 0 754 1 0 0 1089 0
chr22:24133967 SMARCB1 p.R40 C 0 502 0 0 0 446 0 0 1 732 0 0
chr22:24133990 SMARCB1 p.Y47 C 0 578 0 0 1 557 0 0 0 919 0 0
chr22:24134006 SMARCB1 p.R53 C 0 595 0 0 2 544 0 0 0 876 0 0
chr22:24143240 SMARCB1 p.R158 C 0 355 0 0 0 371 0 0 0 427 0 0
chr22:24145582 SMARCB1 p.R201 C 0 507 0 0 1 467 0 0 1 672 0 0
chr22:24176339 SMARCB1 p.R377 G 0 0 266 0 0 0 260 0 0 0 533 0
chr2:209113106 IDH1 p.A134 G 0 0 235 0 0 0 343 3 0 1 390 0
chr2:209113108 IDH1 p.H133 A 241 0 0 0 392 0 0 0 400 1 0 0
chr2:209113111 IDH1 p.R132 A 253 0 0 1 366 1 0 0 344 0 0 0
chr2:209113112 IDH1 p.R132 C 0 293 0 0 1 390 0 0 1 379 0 0
chr2:209113113 IDH1 p.R132 G 0 2 276 0 0 0 359 1 0 0 373 4
chr2:209113117 IDH1 p.I130 T 0 0 0 287 0 0 0 414 0 0 1 386
chr2:209113139 IDH1 p.G123 C 1 393 0 0 1 486 0 0 3 364 0 0
chr2:209113140 IDH1 p.G123 C 1 387 0 0 3 491 0 0 3 357 0 0
chr2:209113151 IDH1 p.R119 C 0 425 0 0 4 477 1 0 0 348 0 0
chr2:209113160 IDH1 p.N116 T 0 0 0 412 0 0 0 554 0 0 0 394
chr2:209113192 IDH1 p.G105 G 0 0 468 0 0 0 543 0 0 0 452 1
chr2:212288940 ERBB4 p.G936 C 0 637 0 0 0 799 0 0 2 863 0 0
chr2:212288942 ERBB4 p.K935 T 1 0 0 635 0 0 0 851 2 0 1 865
chr2:212288955 ERBB4 p.D931 C 0 642 0 0 3 807 0 0 0 852 0 0
chr2:212530066 ERBB4 p.H618 T 0 0 0 447 0 0 1 509 0 0 1 833
chr2:212530135 ERBB4 p.D595 T 0 0 1 686 1 0 0 920 0 0 1 813
chr2:212576857 ERBB4 p.V348 C 0 584 0 2 3 721 0 1 0 515 0 0
chr2:212576877 ERBB4 p.S341 G 0 0 509 0 0 0 680 0 0 0 521 1
chr2:212578341 ERBB4 p.R306 G 0 1 198 0 0 0 338 0 1 0 337 1
chr2:212578349 ERBB4 p.S303 G 0 0 175 3 0 0 343 0 0 0 342 0
chr2:212587147 ERBB4 p.Y285 T 0 0 0 556 0 2 0 827 0 0 0 774
chr2:212589811 ERBB4 p.T244 G 0 0 506 0 0 0 631 1 0 0 621 0
chr2:212652764 ERBB4 p.N181 T 1 0 0 461 0 0 0 502 0 0 1 726
chr2:212812157 ERBB4 p.T140 G 0 0 517 0 0 1 520 0 0 0 644 0
chr2:29432664 ALK p.R1275 C 0 352 0 0 0 415 0 0 0 470 0 0
chr2:29443631 ALK p.L1196 G 0 0 486 0 0 0 405 0 0 0 557 0
chr2:29443695 ALK p.F1174 G 0 0 524 0 0 0 539 2 0 0 657 1
chr2:29443696 ALK p.F1174 A 530 0 0 0 585 0 0 0 692 1 0 0
chr2:29443697 ALK p.F1174 A 509 0 0 1 558 0 0 0 676 1 0 1
chr3:10183772 VHL p.P81 C 0 145 0 0 0 217 0 0 0 358 0 0
chr3:10183775 VHL p.R82 C 0 148 0 0 0 206 0 0 1 350 0 0
chr3:10183776 VHL p.R82 G 0 0 151 0 0 0 216 0 0 0 338 0
chr3:10183785 VHL p.L85 T 0 0 0 123 0 0 0 188 0 0 2 290
chr3:10183787 VHL p.P86 C 0 145 0 0 0 211 0 0 0 370 0 0
chr3:10183788 VHL p.P86 C 0 146 0 0 0 185 0 0 0 361 1 0
chr3:10183793 VHL p.W88 T 0 0 0 116 0 1 0 183 0 0 1 286
chr3:10183794 VHL p.W88 G 0 0 150 0 0 0 203 0 1 0 323 0
chr3:10183795 VHL p.W88 G 0 0 152 0 0 0 201 0 1 0 333 1
chr3:10183797 VHL p.L89 T 0 0 0 121 0 0 0 170 0 0 2 242
chr3:10183800 VHL p.N90 A 120 1 0 0 156 0 0 0 247 1 0 0
chr3:10183808 VHL p.G93 G 0 0 141 0 0 0 196 0 0 0 327 0
chr3:10183815 VHL p.P95 C 0 138 0 0 0 196 0 0 0 354 0 0
chr3:10183817 VHL p.Q96 C 0 145 0 0 0 201 0 0 0 367 0 0
chr3:10183824 VHL p.Y98 A 95 1 0 0 140 0 0 0 277 4 0 0
chr3:10183825 VHL p.Y98 C 0 138 0 0 0 188 0 0 0 364 0 0
chr3:10183832 VHL p.L101 C 0 150 0 0 0 181 0 0 0 328 0 0
chr3:10183833 VHL p.L101 T 0 0 1 124 0 0 0 160 0 0 0 231
chr3:10188198 VHL p.G114 G 0 0 377 0 0 0 392 0 0 0 396 3
chr3:10188200 VHL p.H115 C 0 409 0 0 0 412 0 0 0 375 0 0
chr3:10188206 VHL p.W117 T 0 0 0 393 0 0 0 474 2 0 0 407
chr3:10188207 VHL p.W117 G 0 0 413 0 0 0 446 0 0 0 400 0
chr3:10188208 VHL p.W117 G 0 0 400 0 0 0 421 0 0 0 394 2
chr3:10188210 VHL p.L118 T 0 0 0 364 0 0 0 440 0 0 0 376
chr3:10188214 VHL p.F119 C 0 423 0 0 0 461 0 0 0 390 0 0
chr3:10188218 VHL p.D121 G 0 0 436 0 0 0 461 0 0 0 416 0
chr3:10188219 VHL p.D121 A 394 0 0 0 429 1 0 1 367 2 1 0
chr3:10188220 VHL p.D121 T 0 0 0 407 0 0 0 463 0 0 2 407
chr3:10188222 VHL p.A122 C 0 423 0 0 3 474 1 0 0 399 0 0
chr3:10188234 VHL p.D126 A 430 0 0 0 505 1 0 0 474 1 0 0
chr3:10188240 VHL p.L128 T 0 0 1 391 0 0 0 469 1 0 2 472
chr3:10188245 VHL p.V130 G 0 0 438 1 0 0 512 0 0 0 492 1
chr3:10188250 VHL p.N131 C 0 465 0 0 0 516 0 1 1 488 0 0
chr3:10188251 VHL p.Q132 C 0 474 0 0 0 508 0 0 0 473 0 0
chr3:10188257 VHL p.E134 G 0 0 465 0 0 0 520 0 0 0 501 1
chr3:10188263 VHL p.F136 T 0 0 0 459 0 0 0 564 1 0 0 531
chr3:10188270 VHL p.P138 C 0 447 0 0 0 507 0 0 2 457 0 0
chr3:10188274 VHL p.S139 T 0 0 0 463 0 0 1 546 1 0 1 522
chr3:10188286 VHL p.D143 C 0 460 0 2 1 483 0 0 1 478 0 0
chr3:10188287 VHL p.G144 G 0 0 440 1 0 1 459 1 0 0 451 2
chr3:10188295 VHL p.P146 T 0 0 0 466 0 0 1 551 0 0 1 487
chr3:10191477 VHL p.T157 C 0 451 0 0 0 420 0 0 1 495 0 0
chr3:10191478 VHL p.T157 T 0 0 0 429 0 0 1 437 0 0 0 485
chr3:10191479 VHL p.L158 C 1 451 0 0 2 411 0 0 2 477 0 0
chr3:10191480 VHL p.L158 T 0 1 0 430 0 0 0 433 0 1 1 473
chr3:10191485 VHL p.E160 G 0 0 447 0 0 0 421 0 0 0 471 0
chr3:10191488 VHL p.R161 C 0 443 0 0 0 390 0 0 0 437 0 1
chr3:10191489 VHL p.R161 G 0 0 443 1 0 0 390 2 0 0 435 0
chr3:10191491 VHL p.C162 T 1 0 1 424 0 0 0 420 0 0 0 438
chr3:10191492 VHL p.C162 G 0 0 430 0 0 0 429 1 0 0 474 0
chr3:10191493 VHL p.C162 C 1 433 0 0 0 396 0 0 0 485 0 0
chr3:10191495 VHL p.L163 T 0 0 0 437 0 0 0 424 0 0 0 470
chr3:10191497 VHL p.Q164 C 0 458 0 0 0 384 0 0 2 443 0 0
chr3:10191498 VHL p.Q164 A 445 0 0 1 430 0 0 0 472 0 0 0
chr3:10191499 VHL p.Q164 G 0 0 459 1 0 0 403 0 0 0 494 0
chr3:10191503 VHL p.V166 G 0 0 461 0 0 0 430 0 0 0 483 0
chr3:10191504 VHL p.V166 T 0 0 1 419 0 0 1 412 0 0 1 449
chr3:10191506 VHL p.R167 C 0 442 0 0 0 381 0 0 1 442 0 0
chr3:10191507 VHL p.R167 G 0 0 462 2 0 1 377 0 0 0 441 0
chr3:10191512 VHL p.L169 C 1 460 0 0 1 419 0 0 1 466 0 0
chr3:10191513 VHL p.L169 T 0 0 0 465 0 0 0 433 0 0 1 466
chr3:10191520 VHL p.K171 G 0 0 477 1 0 0 431 1 0 0 477 1
chr3:178916725 PIK3CA p.R38 C 1 437 0 0 0 534 0 0 1 513 0 0
chr3:178916726 PIK3CA p.R38 G 0 0 435 0 0 0 551 3 0 0 521 0
chr3:178916727 PIK3CA p.R38 T 0 0 0 416 1 0 1 579 0 0 0 514
chr3:178916791 PIK3CA p.Q60 C 1 450 0 0 0 608 0 0 1 410 0 0
chr3:178916836 PIK3CA p.Q75 C 0 419 0 0 2 597 0 0 2 371 0 0
chr3:178916851 PIK3CA p.E80 G 0 0 389 0 0 1 545 1 0 0 315 1
chr3:178916854 PIK3CA p.E81 G 0 0 345 0 0 0 539 1 0 0 314 1
chr3:178916855 PIK3CA p.E81 A 370 0 1 0 608 0 0 0 386 0 0 0
chr3:178916856 PIK3CA p.E81 A 360 0 0 0 595 0 0 0 378 0 0 1
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chr3:178916875 PIK3CA p.R88 C 0 299 0 0 1 476 0 0 0 365 0 0
chr3:178916876 PIK3CA p.R88 G 0 0 290 0 0 1 467 0 0 0 345 1
chr3:178916877 PIK3CA p.R88 A 273 1 0 0 451 0 0 1 358 0 0 0
chr3:178916890 PIK3CA p.R93 C 0 251 0 0 0 401 0 0 1 297 0 0
chr3:178916891 PIK3CA p.R93 G 0 0 242 0 0 1 378 1 0 0 293 1
chr3:178916892 PIK3CA p.R93 G 0 0 240 0 0 0 391 1 0 0 296 2
chr3:178916935 PIK3CA p.R108 C 0 192 0 0 3 267 0 0 1 248 0 0
chr3:178916936 PIK3CA p.R108 G 0 0 187 0 0 0 288 1 0 0 254 0
chr3:178916937 PIK3CA p.R108 T 0 0 0 165 0 0 0 307 0 0 1 230
chr3:178916941 PIK3CA p.E110 G 0 0 179 0 0 0 300 0 0 0 253 0
chr3:178916944 PIK3CA p.K111 A 164 1 0 0 304 0 0 0 232 0 0 0
chr3:178916945 PIK3CA p.K111 A 167 0 0 0 305 0 0 0 244 0 0 0
chr3:178916946 PIK3CA p.K111 G 0 0 160 0 0 0 296 0 0 0 241 0
chr3:178916948 PIK3CA p.I112 T 0 0 0 160 0 0 0 278 0 0 1 241
chr3:178916957 PIK3CA p.R115 G 1 0 137 0 0 0 210 1 0 0 238 1
chr3:178916965 PIK3CA p.G118 G 0 0 111 0 0 1 173 0 0 0 197 2
chr3:178917478 PIK3CA p.G118 G 0 0 300 0 0 0 348 0 0 1 431 0
chr3:178917479 PIK3CA p.G118 T 0 0 0 274 0 0 0 344 0 0 2 425
chr3:178921489 PIK3CA p.T324 C 0 489 0 0 0 577 0 0 0 565 0 0
chr3:178921549 PIK3CA p.V344 T 0 0 0 230 0 0 0 289 0 0 1 405
chr3:178921551 PIK3CA p.N345 A 254 0 0 0 319 0 0 0 375 0 0 0
chr3:178921552 PIK3CA p.N345 A 225 0 0 0 291 1 0 0 374 0 0 0
chr3:178921553 PIK3CA p.N345 T 0 0 0 230 0 0 1 299 1 0 0 365
chr3:178927451 PIK3CA p.S405 C 0 206 0 0 0 276 0 0 0 289 0 0
chr3:178927458 PIK3CA p.C407 C 0 192 0 0 0 258 0 0 0 282 0 0
chr3:178927974 PIK3CA p.E418 G 0 0 114 0 0 0 143 0 0 0 84 1
chr3:178927980 PIK3CA p.C420 T 0 0 0 113 0 0 0 171 0 0 0 103
chr3:178927981 PIK3CA p.C420 G 0 0 112 0 0 0 165 0 0 0 112 0
chr3:178927982 PIK3CA p.C420 T 0 0 0 109 0 0 0 176 0 0 0 113
chr3:178928079 PIK3CA p.E453 G 0 0 122 0 0 0 204 0 0 0 181 0
chr3:178928080 PIK3CA p.E453 A 126 0 0 0 217 0 0 0 184 1 0 0
chr3:178928093 PIK3CA p.N457 C 0 102 0 0 1 186 0 0 0 163 0 0
chr3:178928118 PIK3CA p.P466 C 0 88 0 0 2 146 0 0 1 143 0 0
chr3:178936073 PIK3CA p.P539 C 0 371 0 0 0 427 0 0 0 252 0 0
chr3:178936074 PIK3CA p.P539 C 0 380 0 0 0 425 0 0 0 248 0 0
chr3:178936075 PIK3CA p.P539 T 0 0 0 382 0 0 0 439 0 0 1 265
chr3:178936082 PIK3CA p.E542 G 0 0 369 0 0 0 446 0 0 0 251 0
chr3:178936083 PIK3CA p.E542 A 368 0 0 0 439 0 0 0 252 1 0 0
chr3:178936084 PIK3CA p.E542 A 359 0 0 0 444 0 0 0 261 0 0 0
chr3:178936089 PIK3CA p.T544 C 0 377 0 0 1 420 0 0 0 245 0 0
chr3:178936091 PIK3CA p.E545 G 0 0 368 0 0 0 418 0 0 0 252 0
chr3:178936092 PIK3CA p.E545 A 336 0 0 0 403 0 0 0 217 0 0 0
chr3:178936093 PIK3CA p.E545 G 0 0 358 0 0 0 402 0 0 0 237 0
chr3:178936094 PIK3CA p.Q546 C 0 351 0 0 0 390 0 0 0 241 0 0
chr3:178936095 PIK3CA p.Q546 A 356 0 0 0 437 0 0 0 237 1 0 0
chr3:178936096 PIK3CA p.Q546 G 0 0 356 0 0 0 408 0 0 0 244 1
chr3:178936103 PIK3CA p.D549 G 0 0 351 0 0 0 421 0 0 0 231 1
chr3:178936104 PIK3CA p.D549 A 331 0 0 0 403 0 0 0 237 0 0 0
chr3:178936105 PIK3CA p.D549 T 0 0 0 317 0 0 0 391 0 0 0 205
chr3:178938860 PIK3CA p.H701 A 248 0 0 0 327 0 0 0 252 2 0 0
chr3:178947827 PIK3CA p.C901 G 0 2 330 1 0 0 426 0 0 0 312 0
chr3:178947850 PIK3CA p.F909 T 0 0 0 344 0 0 0 498 0 0 0 465
chr3:178947852 PIK3CA p.F909 C 0 355 0 0 0 499 0 0 0 466 0 0
chr3:178952004 PIK3CA p.A1020 C 2 450 0 0 3 554 0 0 0 556 0 0
chr3:178952006 PIK3CA p.Y1021 T 0 0 0 454 2 0 0 605 0 0 0 582
chr3:178952007 PIK3CA p.Y1021 A 435 0 0 0 611 0 0 0 597 1 0 0
chr3:178952008 PIK3CA p.Y1021 C 0 441 0 0 0 578 0 0 1 554 0 0
chr3:178952013 PIK3CA p.R1023 G 4 0 433 0 0 0 527 0 0 0 535 2
chr3:178952018 PIK3CA p.T1025 A 412 0 0 0 496 0 1 0 514 2 0 0
chr3:178952019 PIK3CA p.T1025 C 1 439 0 0 0 532 0 0 3 557 0 0
chr3:178952020 PIK3CA p.T1025 C 0 416 0 0 2 502 0 0 4 498 0 0
chr3:178952030 PIK3CA p.D1029 G 0 0 461 0 0 0 564 0 0 0 576 2
chr3:178952049 PIK3CA p.A1035 C 0 406 0 0 2 549 0 0 1 522 0 0
chr3:178952060 PIK3CA p.F1039 T 0 0 0 350 0 0 0 532 0 0 0 508
chr3:178952065 PIK3CA p.M1040 G 0 0 361 0 0 0 494 0 0 0 477 1
chr3:178952072 PIK3CA p.M1043 A 322 1 0 0 491 1 0 0 487 0 0 0
chr3:178952073 PIK3CA p.M1043 T 0 0 0 330 0 0 0 499 0 0 0 507
chr3:178952074 PIK3CA p.M1043 G 0 0 316 0 0 0 460 0 0 0 470 1
chr3:178952075 PIK3CA p.N1044 A 311 0 0 1 471 0 0 0 480 0 0 0
chr3:178952077 PIK3CA p.N1044 T 0 0 0 319 0 0 0 463 1 0 1 498
chr3:178952078 PIK3CA p.D1045 G 0 0 316 0 0 0 425 2 0 0 463 1
chr3:178952081 PIK3CA p.A1046 G 0 0 304 0 0 0 400 0 0 0 431 3
chr3:178952082 PIK3CA p.A1046 C 1 298 0 0 1 390 0 0 1 441 0 0
chr3:178952084 PIK3CA p.H1047 C 1 273 0 0 0 372 0 0 0 458 0 0
chr3:178952085 PIK3CA p.H1047 A 275 1 0 0 408 0 0 0 465 0 0 1
chr3:178952086 PIK3CA p.H1047 T 0 0 0 261 0 0 1 409 0 0 1 469
chr3:178952088 PIK3CA p.H1048 A 272 0 0 1 409 0 0 2 439 0 0 1
chr3:178952090 PIK3CA p.G1049 G 0 0 257 0 0 0 355 0 0 0 380 3
chr3:178952091 PIK3CA p.G1049 G 0 0 258 0 0 0 356 0 0 0 414 0
chr3:178952092 PIK3CA p.G1049 T 0 0 0 224 0 0 0 355 0 0 2 391
chr3:178952152 PIK3CA p.*1069 A 113 1 0 0 190 0 0 0 243 1 0 0
chr3:37067240 MLH1 p.V384 T 0 0 1 377 0 0 0 378 0 0 0 416
chr3:41266040 CTNNB1 p.A13 G 0 0 524 0 0 0 602 1 0 0 586 0
chr3:41266046 CTNNB1 p.E15 G 0 2 536 1 0 0 625 0 0 0 599 1
chr3:41266062 CTNNB1 p.A20 C 1 557 0 0 2 627 0 0 1 597 1 0
chr3:41266064 CTNNB1 p.A21 G 0 0 563 0 0 2 656 4 0 0 617 2
chr3:41266067 CTNNB1 p.V22 G 0 0 572 0 0 1 675 0 0 0 643 1
chr3:41266068 CTNNB1 p.V22 T 0 0 0 528 0 0 0 689 0 0 1 596
chr3:41266070 CTNNB1 p.S23 A 572 1 0 0 748 0 0 0 667 1 2 0
chr3:41266077 CTNNB1 p.W25 G 0 0 586 0 0 0 659 0 0 0 630 1
chr3:41266089 CTNNB1 p.S29 C 0 662 0 0 0 726 0 0 1 738 1 0
chr3:41266093 CTNNB1 p.Y30 C 0 621 0 0 3 708 0 0 4 752 0 0
chr3:41266094 CTNNB1 p.L31 C 1 613 0 0 2 696 0 0 1 710 0 0
chr3:41266097 CTNNB1 p.D32 G 0 0 633 0 0 0 713 2 0 0 732 2
chr3:41266098 CTNNB1 p.D32 A 589 2 0 0 699 1 0 0 698 2 0 0
chr3:41266100 CTNNB1 p.S33 T 0 0 0 640 0 0 0 733 0 0 2 708
chr3:41266101 CTNNB1 p.S33 C 0 680 0 0 0 745 0 0 1 730 0 0
chr3:41266103 CTNNB1 p.G34 G 0 0 638 0 0 0 684 0 0 0 698 1
chr3:41266104 CTNNB1 p.G34 G 0 0 664 0 0 0 721 2 0 0 736 1
chr3:41266107 CTNNB1 p.I35 T 0 0 1 658 0 1 0 764 0 0 1 771
chr3:41266109 CTNNB1 p.H36 C 0 634 1 0 1 715 0 0 1 706 0 0
chr3:41266110 CTNNB1 p.H36 A 631 1 0 0 764 0 0 1 784 1 0 0
chr3:41266112 CTNNB1 p.S37 T 0 0 0 650 0 0 0 775 0 0 1 774
chr3:41266113 CTNNB1 p.S37 C 0 672 0 0 1 708 0 0 3 779 0 0
chr3:41266115 CTNNB1 p.G38 G 0 0 642 0 0 0 687 0 0 0 733 1
chr3:41266116 CTNNB1 p.G38 G 0 0 635 1 0 0 693 1 0 0 726 0
chr3:41266117 CTNNB1 p.G38 T 1 0 0 615 0 0 0 713 0 0 0 715
chr3:41266118 CTNNB1 p.A39 G 0 0 671 0 0 0 724 0 0 0 786 2
chr3:41266119 CTNNB1 p.A39 C 3 635 0 0 1 703 0 0 1 769 0 0
chr3:41266122 CTNNB1 p.T40 C 1 685 0 0 0 764 0 0 0 822 0 0
chr3:41266123 CTNNB1 p.T40 T 0 0 0 660 0 0 0 776 0 0 1 843
chr3:41266124 CTNNB1 p.T41 A 631 0 0 1 765 1 0 1 771 4 0 0
chr3:41266125 CTNNB1 p.T41 C 1 692 0 0 1 745 0 0 1 855 0 0
chr3:41266126 CTNNB1 p.T41 C 0 664 0 0 3 728 0 0 6 792 0 0
chr3:41266128 CTNNB1 p.T42 C 0 682 0 0 3 721 0 0 0 828 0 0
chr3:41266130 CTNNB1 p.A43 G 0 0 679 0 0 0 730 1 0 1 852 1
chr3:41266131 CTNNB1 p.A43 C 0 685 0 0 0 723 0 0 0 839 0 0
chr3:41266133 CTNNB1 p.P44 C 1 656 0 0 2 720 0 0 1 808 0 0
chr3:41266134 CTNNB1 p.P44 C 1 675 0 0 1 725 0 0 1 781 0 0
chr3:41266136 CTNNB1 p.S45 T 0 0 1 640 0 0 1 737 0 0 3 783
chr3:41266137 CTNNB1 p.S45 C 2 687 0 0 0 742 0 0 2 844 0 0
chr3:41266141 CTNNB1 p.L46 G 0 0 689 0 0 0 762 0 0 0 759 1
chr4:153245446 FBXW7 p.S582 G 0 0 406 0 1 0 553 1 0 0 624 1
chr4:153247288 FBXW7 p.R505 C 2 371 0 0 0 405 0 1 0 666 0 0
chr4:153247289 FBXW7 p.R505 G 0 0 368 1 0 0 407 0 0 0 623 0
chr4:153247292 FBXW7 p.V504 C 0 411 0 0 0 487 0 0 0 700 0 0
chr4:153247366 FBXW7 p.R479 C 0 254 0 0 0 305 0 0 0 250 0 0
chr4:153249384 FBXW7 p.R465 C 0 214 0 1 0 213 0 0 0 133 0 0
chr4:153249385 FBXW7 p.R465 G 0 0 209 0 0 0 216 0 0 1 114 0
chr4:153250883 FBXW7 p.R393 G 0 0 226 1 0 0 348 1 0 0 253 0
chr4:153258983 FBXW7 p.R278 G 0 0 159 0 0 0 224 1 0 0 234 0
chr4:1803564 FGFR3 p.R248 C 1 79 0 0 0 69 0 0 1 127 0 0
chr4:1803568 FGFR3 p.S249 C 0 93 0 0 0 75 0 0 0 147 0 0
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chr4:1803575 FGFR3 p.H251 C 0 88 0 0 0 75 0 0 0 146 0 0
chr4:1806088 FGFR3 p.A369 G 0 0 71 0 0 0 82 0 0 0 83 0
chr4:1806089 FGFR3 p.G370 G 0 0 77 0 0 0 91 0 0 0 86 0
chr4:1806092 FGFR3 p.S371 A 67 0 0 0 85 0 0 0 71 0 0 1
chr4:1806099 FGFR3 p.Y373 A 68 0 0 0 84 1 0 0 101 1 0 0
chr4:1806119 FGFR3 p.G380 G 0 0 94 0 0 0 105 0 0 0 109 0
chr4:1806131 FGFR3 p.F384 T 0 0 0 103 0 0 0 111 0 0 0 90
chr4:1806153 FGFR3 p.A391 C 0 116 0 0 0 122 0 0 0 111 0 0
chr4:1807862 FGFR3 p.D641 G 0 0 238 0 0 0 200 0 0 0 276 0
chr4:1807889 FGFR3 p.K650 A 280 0 0 1 246 0 0 0 228 0 0 0
chr4:1807890 FGFR3 p.K650 A 263 0 0 0 199 0 0 0 222 0 0 0
chr4:1808331 FGFR3 p.G697 G 0 0 355 0 0 0 307 1 0 0 414 0
chr4:1808949 FGFR3 p.L794 T 0 0 0 291 0 0 0 263 0 0 0 432
chr4:55141036 PDGFRA p.V561 T 0 0 1 352 0 0 1 420 0 0 4 579
chr4:55144146 PDGFRA p.N659 A 364 0 0 0 551 1 2 0 311 1 0 0
chr4:55144148 PDGFRA p.N659 C 0 393 0 0 0 547 0 0 0 342 0 0
chr4:55144547 PDGFRA p.T674 C 0 313 0 0 0 401 0 0 0 444 0 0
chr4:55152040 PDGFRA p.V824 C 0 140 0 312 1 140 1 376 1 151 1 402
chr4:55152092 PDGFRA p.D842 G 0 0 467 0 0 0 480 0 0 0 547 0
chr4:55152093 PDGFRA p.D842 A 412 0 0 0 471 0 0 0 519 2 0 0
chr4:55152094 PDGFRA p.D842 C 0 437 1 0 0 454 0 0 0 507 0 0
chr4:55152095 PDGFRA p.I843 A 435 0 0 1 482 0 0 0 504 2 1 0
chr4:55152096 PDGFRA p.I843 T 0 0 0 431 0 0 0 459 0 0 1 515
chr4:55152097 PDGFRA p.I843 C 1 438 0 0 0 454 0 0 0 494 0 0
chr4:55152098 PDGFRA p.M844 A 433 1 0 0 462 0 0 0 487 1 0 0
chr4:55152099 PDGFRA p.M844 T 0 0 0 423 0 0 0 471 2 0 1 498
chr4:55152100 PDGFRA p.M844 G 0 0 436 0 0 0 447 1 0 0 476 2
chr4:55152101 PDGFRA p.H845 C 0 429 0 0 0 444 0 0 2 478 0 0
chr4:55152102 PDGFRA p.H845 A 416 0 0 0 469 0 0 0 485 1 0 1
chr4:55152103 PDGFRA p.H845 T 0 0 0 398 0 0 0 462 1 0 0 469
chr4:55152104 PDGFRA p.D846 G 0 0 425 0 0 0 448 0 0 0 449 0
chr4:55152105 PDGFRA p.D846 A 413 0 0 0 469 1 0 1 479 1 0 0
chr4:55152106 PDGFRA p.D846 T 0 2 0 402 0 0 0 453 0 0 2 454
chr4:55561763 KIT p.G51 C 0 339 0 0 1 363 0 0 1 352 0 0
chr4:55561764 KIT p.D52 G 0 0 338 0 1 0 361 0 0 0 329 0
chr4:55592202 KIT p.K509 A 508 0 0 0 608 0 0 0 654 0 0 0
chr4:55593431 KIT p.V530 G 0 0 339 1 0 1 538 1 0 0 624 1
chr4:55593464 KIT p.M541 A 276 118 0 0 513 150 2 0 596 229 0 0
chr4:55593481 KIT p.K546 A 453 0 0 0 734 0 0 0 868 2 0 0
chr4:55593586 KIT p.P551 C 1 498 0 0 1 669 0 0 1 780 0 0
chr4:55593588 KIT p.M552 A 519 0 0 0 737 0 0 0 813 1 0 0
chr4:55593591 KIT p.Y553 T 2 1 0 517 0 0 0 726 0 0 0 871
chr4:55593594 KIT p.E554 G 0 0 516 0 0 0 688 0 0 0 829 1
chr4:55593597 KIT p.V555 G 0 0 495 0 0 0 669 1 2 0 855 0
chr4:55593603 KIT p.W557 T 0 0 3 468 0 0 0 619 0 0 3 753
chr4:55593604 KIT p.W557 G 0 0 485 1 0 0 596 0 0 0 737 1
chr4:55593605 KIT p.W557 G 0 0 499 0 0 0 616 0 0 0 775 4
chr4:55593606 KIT p.K558 A 482 1 0 0 662 0 0 0 749 1 0 0
chr4:55593607 KIT p.K558 A 457 0 0 0 607 0 0 0 708 0 0 1
chr4:55593608 KIT p.K55 G 0 0 481 1 0 0 602 0 0 0 727 2
chr4:55593609 KIT p.V559 G 0 0 486 2 0 0 613 1 0 0 742 2
chr4:55593610 KIT p.V559 T 1 0 1 415 0 0 1 561 0 0 3 674
chr4:55593613 KIT p.V560 T 1 0 0 436 1 0 0 594 1 0 0 680
chr4:55593614 KIT p.V560 T 0 0 0 444 0 0 1 620 0 0 1 709
chr4:55593615 KIT p.E561 G 0 1 471 0 0 0 583 0 0 0 703 4
chr4:55593617 KIT p.E561 G 0 0 462 0 0 0 573 0 0 0 669 4
chr4:55593618 KIT p.E562 G 0 0 466 0 0 0 558 2 0 0 699 4
chr4:55593630 KIT p.N566 A 429 0 0 0 579 0 0 0 659 2 0 0
chr4:55593632 KIT p.N566 C 2 471 0 0 0 565 0 0 3 699 0 0
chr4:55593635 KIT p.N567 T 0 0 0 462 0 0 0 599 0 0 0 741
chr4:55593636 KIT p.Y568 T 0 0 0 453 0 0 0 567 0 0 0 710
chr4:55593648 KIT p.D572 G 0 0 453 0 0 0 542 0 0 0 699 2
chr4:55593652 KIT p.P573 C 0 434 0 0 2 513 0 0 2 633 1 0
chr4:55593660 KIT p.L576 C 0 485 0 0 4 548 1 0 0 646 0 0
chr4:55593661 KIT p.L576 T 0 0 0 472 0 0 0 568 1 0 1 633
chr4:55593663 KIT p.P577 C 1 488 0 0 3 548 0 0 2 612 0 0
chr4:55593679 KIT p.W582 G 0 0 488 0 0 0 504 2 0 0 570 1
chr4:55593680 KIT p.W582 G 0 2 465 0 0 0 482 0 0 0 567 1
chr4:55593685 KIT p.F584 T 0 0 1 448 1 0 0 555 0 0 1 551
chr4:55593689 KIT p.P585 C 0 459 0 0 2 504 0 0 0 534 0 0
chr4:55594221 KIT p.K642 A 539 0 0 0 604 1 0 0 682 0 0 0
chr4:55594225 KIT p.V643 T 0 0 1 527 0 0 1 559 0 0 1 669
chr4:55594258 KIT p.V654 T 0 0 0 620 0 0 0 616 0 0 0 484
chr4:55595518 KIT p.T670 A 407 0 0 0 584 0 0 0 522 0 0 1
chr4:55595519 KIT p.T670 C 0 421 0 0 0 538 0 0 0 496 0 0
chr4:55599307 KIT p.F811 T 1 0 0 539 0 0 0 661 0 0 0 554
chr4:55599320 KIT p.D816 G 0 0 551 0 0 0 614 3 0 0 578 1
chr4:55599321 KIT p.D816 A 524 0 0 1 635 0 0 0 571 0 2 0
chr4:55599322 KIT p.D816 C 0 562 0 0 0 624 0 0 3 544 0 0
chr4:55599327 KIT p.K818 A 553 0 0 0 644 0 0 0 566 0 0 0
chr4:55599332 KIT p.D820 G 0 0 559 0 0 1 635 1 0 0 535 1
chr4:55599333 KIT p.D820 A 539 0 0 0 661 0 0 0 558 1 0 0
chr4:55599334 KIT p.D820 T 0 0 0 509 0 0 1 648 0 0 0 524
chr4:55599338 KIT p.N822 A 515 0 0 0 643 0 0 0 538 0 0 0
chr4:55599340 KIT p.N822 T 0 0 0 502 0 0 0 629 0 0 0 543
chr4:55599341 KIT p.Y823 T 1 0 0 507 0 1 0 636 0 0 0 552
chr4:55599342 KIT p.Y823 A 490 1 0 2 599 0 0 0 514 1 0 2
chr4:55599347 KIT p.V825 G 0 0 510 0 0 0 569 0 0 0 551 1
chr4:55599348 KIT p.V825 T 0 0 0 423 1 0 0 545 1 1 0 487
chr4:55602694 KIT p.E839 G 0 0 564 1 0 0 688 0 0 0 641 0
chr4:55602737 KIT p.W853 G 0 0 569 0 0 0 657 3 0 0 685 1
chr4:55946257 KDR p.G1308 C 0 421 0 0 0 392 0 0 0 433 0 1
chr4:55953807 KDR p.P1210 G 0 0 352 1 0 0 338 1 1 0 345 0
chr4:55955111 KDR p.G1145 C 0 351 0 0 0 386 0 0 2 482 0 0
chr4:55955127 KDR p.L1140 G 0 0 342 1 0 0 356 0 0 0 555 0
chr4:55960989 KDR p.S984 C 0 405 0 0 0 370 0 0 0 529 0 0
chr4:55961023 KDR p.A973 C 1 389 0 0 1 388 0 0 1 497 0 0
chr4:55962507 KDR p.G873 C 1 406 0 0 0 551 0 0 0 482 0 0
chr4:55972964 KDR p.V476 C 1 579 0 0 0 665 0 0 1 433 0 0
chr4:55979623 KDR p.R275 C 0 377 0 0 0 405 0 0 0 496 0 0
chr4:55980348 KDR p.A248 G 0 0 533 0 0 0 619 0 0 0 643 2
chr5:112173917 APC p.R876 C 0 531 0 0 1 544 0 0 1 609 0 1
chr5:112173930 APC p.I880 T 0 0 0 472 0 0 0 530 0 0 4 550
chr5:112173947 APC p.Q886 C 1 496 0 0 1 500 0 0 0 481 0 0
chr5:112174577 APC p.Q1096 C 2 686 0 0 0 754 1 0 1 736 0 0
chr5:112174631 APC p.R1114 C 0 667 0 0 1 737 1 0 1 775 0 0
chr5:112174650 APC p.G1120 G 0 0 696 0 0 0 786 1 0 0 734 3
chr5:112175162 APC p.Q1291 C 0 641 0 0 1 621 2 0 0 598 1 0
chr5:112175171 APC p.Q1294 C 0 660 0 0 1 609 0 0 2 618 1 0
chr5:112175174 APC p.E1295 G 0 0 648 1 0 0 592 0 0 0 581 0
chr5:112175193 APC p.T1301 C 1 754 0 0 0 640 0 0 2 742 0 0
chr5:112175198 APC p.Q1303 C 0 781 0 0 0 689 0 0 4 719 0 0
chr5:112175207 APC p.E1306 G 0 0 774 1 0 0 722 1 0 0 722 3
chr5:112175213 APC p.K1308 A 777 0 0 0 781 0 0 0 749 0 0 0
chr5:112175216 APC p.E1309 G 0 0 825 1 0 1 768 0 0 0 741 0
chr5:112175219 APC p.K1310 A 792 1 0 0 769 0 0 0 715 2 0 0
chr5:112175225 APC p.G1312 G 0 0 778 1 0 0 700 0 1 0 659 2
chr5:112175235 APC p.S1315 C 0 814 0 0 0 720 0 0 1 713 0 0
chr5:112175240 APC p.E1317 G 0 0 805 0 0 0 723 0 0 0 709 0
chr5:112175255 APC p.E1322 G 0 0 767 0 0 0 633 0 2 0 651 0
chr5:112175303 APC p.Q1338 C 5 659 0 0 1 519 0 0 3 655 0 0
chr5:112175304 APC p.Q1338 A 651 0 2 0 563 1 0 0 658 0 0 0
chr5:112175305 APC p.Q1338 G 0 0 668 1 0 0 521 0 0 0 628 1
chr5:112175324 APC p.E1345 G 0 0 591 0 0 0 495 1 0 0 551 0
chr5:112175328 APC p.S1346 C 1 575 0 0 1 474 0 0 0 555 0 0
chr5:112175339 APC p.K1350 A 528 0 0 0 487 0 0 0 495 1 0 0
chr5:112175348 APC p.E1353 G 0 0 521 0 0 0 436 1 1 0 460 0
chr5:112175354 APC p.S1355 T 0 0 0 522 0 0 0 442 1 0 1 466
chr5:112175358 APC p.S1356 C 3 506 0 0 0 388 0 0 0 436 0 0
chr5:112175388 APC p.A1366 C 0 474 0 0 1 382 0 0 1 474 0 0
chr5:112175390 APC p.Q1367 C 0 470 0 0 3 400 0 0 1 481 0 0
chr5:112175391 APC p.Q1367 A 467 0 1 0 426 0 0 0 488 3 0 0
chr5:112175392 APC p.Q1367 G 1 0 477 0 0 1 403 0 0 0 481 1
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chr5:112175399 APC p.K1370 A 443 1 0 0 435 0 0 0 486 2 0 0
chr5:112175411 APC p.E1374 G 0 0 424 1 0 0 395 0 0 0 454 0
chr5:112175419 APC p.Y1376 T 0 0 0 450 2 0 0 431 0 0 1 480
chr5:112175423 APC p.Q1378 C 0 453 0 0 3 418 0 0 0 501 0 0
chr5:112175426 APC p.E1379 G 0 0 432 0 0 0 391 0 0 1 483 1
chr5:112175576 APC p.Q1429 C 1 434 0 0 2 359 0 0 1 292 0 0
chr5:112175586 APC p.P1432 C 0 428 0 0 2 338 0 0 1 279 0 0
chr5:112175587 APC p.P1432 A 372 1 0 0 292 1 0 0 240 1 0 1
chr5:112175594 APC p.R1435 A 414 0 0 1 347 0 0 0 298 0 0 0
chr5:112175617 APC p.P1442 T 0 0 0 429 0 0 1 361 0 1 0 346
chr5:112175620 APC p.P1443 T 0 0 3 425 0 0 0 370 0 0 1 354
chr5:112175621 APC p.Q1444 C 0 461 0 0 0 370 0 0 2 337 0 0
chr5:112175630 APC p.Q1447 C 0 442 0 0 1 352 0 0 2 346 0 0
chr5:112175639 APC p.R1450 C 0 446 0 0 1 325 0 0 0 350 0 0
chr5:112175642 APC p.E1451 G 0 0 455 0 0 0 352 2 1 0 358 0
chr5:112175651 APC p.K1454 A 442 1 0 0 392 0 0 0 385 0 0 0
chr5:112175672 APC p.E1461 G 0 0 449 0 1 0 359 0 0 0 382 0
chr5:112175681 APC p.E1464 G 0 0 454 0 0 0 354 0 0 0 370 0
chr5:112175696 APC p.Q1469 C 0 432 0 0 0 330 0 0 0 351 0 0
chr5:112175754 APC p.L1488 T 0 0 0 370 0 0 0 433 0 0 0 269
chr5:112175775 APC p.S1495 G 0 0 406 0 0 1 430 1 0 0 299 0
chr5:112175786 APC p.G1499 G 0 0 397 1 0 0 404 1 0 0 246 0
chr5:112175828 APC p.E1513 G 0 0 437 0 0 0 485 0 0 0 352 2
chr5:112175930 APC p.E1547 G 0 0 659 0 0 0 816 1 0 0 488 0
chr5:112175945 APC p.E1552 G 0 0 704 0 0 0 922 0 0 0 563 0
chr5:112175982 APC p.L1564 T 2 0 1 699 0 0 0 1059 0 0 0 545
chr5:112176020 APC p.E1577 G 0 0 683 2 0 1 858 2 0 0 464 0
chr5:149433644 CSF1R p.Y969 A 274 1 0 0 374 0 0 0 506 1 0 0
chr5:149433645 CSF1R p.Y969 T 0 0 1 255 0 0 0 359 0 0 0 496
chr5:149433646 CSF1R p.Y969 A 262 1 0 0 356 0 0 0 477 0 0 0
chr5:149453044 CSF1R p.L301 A 146 2 0 0 158 0 0 0 182 0 0 0
chr5:170837552 NPM1 p.W290 T 0 0 1 124 0 0 0 206 0 0 0 169
chr7:128845101 SMO p.R199 C 0 617 0 0 0 633 0 0 2 633 0 0
chr7:128846040 SMO p.A324 G 0 0 224 0 0 0 201 0 0 0 230 0
chr7:128846374 SMO p.V404 G 0 0 318 0 0 0 388 0 0 0 355 1
chr7:128850341 SMO p.W535 G 0 0 416 0 0 0 368 0 0 0 497 0
chr7:128851593 SMO p.T640 A 265 0 0 1 370 2 0 1 322 2 0 0
chr7:140453112 BRAF p.H608 T 0 0 0 947 0 0 0 1129 0 0 0 784
chr7:140453118 BRAF p.G606 C 0 920 0 0 3 1060 0 0 2 793 0 0
chr7:140453121 BRAF p.S605 C 2 1045 0 0 0 1180 0 0 2 886 0 0
chr7:140453122 BRAF p.S605 T 0 0 0 1009 0 0 0 1253 0 0 0 884
chr7:140453125 BRAF p.W604 A 1005 0 0 0 1195 1 0 0 859 2 0 0
chr7:140453128 BRAF p.R603 G 0 0 988 1 0 0 1074 3 0 0 758 0
chr7:140453132 BRAF p.K601 T 0 0 1 967 0 1 0 1187 1 1 5 860
chr7:140453133 BRAF p.K601 T 0 0 0 980 2 1 0 1229 1 0 0 857
chr7:140453134 BRAF p.K601 T 0 1 0 1009 0 0 0 1218 0 0 1 857
chr7:140453135 BRAF p.V600 C 2 1027 0 0 2 1169 0 0 2 838 1 1
chr7:140453136 BRAF p.V600 A 531 2 0 448 599 1 1 599 470 1 0 362
chr7:140453137 BRAF p.V600 C 1 1029 0 0 0 1169 0 0 0 824 0 0
chr7:140453138 BRAF p.T599 T 1 0 0 1009 0 2 0 1265 2 0 1 815
chr7:140453139 BRAF p.T599 G 0 0 994 0 0 1 1162 0 0 0 811 0
chr7:140453140 BRAF p.T599 T 1 0 0 999 0 0 0 1252 1 0 2 842
chr7:140453142 BRAF p.A598 G 0 0 1007 0 0 0 1160 2 0 0 831 1
chr7:140453144 BRAF p.L597 T 0 2 0 995 0 0 1 1264 1 2 2 881
chr7:140453145 BRAF p.L597 A 993 1 1 0 1265 0 0 2 884 0 0 0
chr7:140453146 BRAF p.L597 G 0 0 1003 0 0 0 1198 1 0 0 818 2
chr7:140453148 BRAF p.G596 C 1 984 0 0 2 1150 0 0 2 816 0 0
chr7:140453149 BRAF p.G596 C 1 947 0 0 1 1090 0 0 1 768 1 0
chr7:140453150 BRAF p.F595 A 978 1 0 0 1249 0 0 0 778 0 1 0
chr7:140453151 BRAF p.F595 A 987 1 0 0 1278 0 0 0 815 1 0 0
chr7:140453152 BRAF p.F595 A 967 2 0 1 1249 1 1 0 866 1 0 0
chr7:140453153 BRAF p.D594 A 950 4 0 0 1208 1 0 0 826 5 0 2
chr7:140453154 BRAF p.D594 T 0 0 0 1011 0 0 0 1288 0 0 0 875
chr7:140453155 BRAF p.D594 C 0 999 0 0 3 1181 0 0 9 814 0 0
chr7:140453159 BRAF p.I592 T 0 0 1 903 0 0 0 1084 0 0 1 763
chr7:140453161 BRAF p.I592 T 0 0 0 956 0 0 0 1187 0 0 2 843
chr7:140453174 BRAF p.D587 G 0 0 942 0 0 0 1011 0 0 0 837 0
chr7:140453175 BRAF p.D587 T 0 0 1 859 0 1 2 982 0 0 1 755
chr7:140453177 BRAF p.E586 T 0 0 0 897 0 0 0 1101 0 0 2 838
chr7:140453179 BRAF p.E586 C 1 924 0 0 2 1049 0 0 1 798 0 0
chr7:140453183 BRAF p.L584 A 897 0 0 2 1064 0 0 0 816 0 0 0
chr7:140453185 BRAF p.L584 G 0 0 907 1 0 0 1029 0 0 0 818 4
chr7:140453186 BRAF p.F583 A 882 0 0 0 1035 0 0 0 828 0 0 0
chr7:140453189 BRAF p.I582 T 0 0 0 926 0 0 1 1065 0 0 0 853
chr7:140453193 BRAF p.N581 T 0 0 0 915 1 0 1 1043 0 0 0 892
chr7:140481397 BRAF p.V471 C 0 829 0 0 0 952 0 0 2 608 0 0
chr7:140481401 BRAF p.G469 T 0 0 0 807 0 0 1 1043 1 0 0 648
chr7:140481402 BRAF p.G469 C 1 854 0 0 1 1016 0 0 0 622 0 0
chr7:140481403 BRAF p.G469 C 0 850 0 1 0 1014 1 0 1 619 0 0
chr7:140481410 BRAF p.G466 T 0 0 0 882 0 0 0 1125 0 0 0 661
chr7:140481411 BRAF p.G466 C 0 898 0 0 2 1084 1 0 0 648 0 0
chr7:140481412 BRAF p.G466 C 2 891 0 0 2 1006 1 0 2 610 0 0
chr7:140481416 BRAF p.G464 T 0 0 0 930 0 0 0 1179 1 0 2 667
chr7:140481417 BRAF p.G464 C 0 935 0 0 2 1085 0 0 0 629 0 0
chr7:140481418 BRAF p.G464 C 1 909 0 0 0 1079 0 0 0 649 0 0
chr7:140481423 BRAF p.R462 C 0 960 0 0 3 1139 1 0 0 699 0 0
chr7:140481451 BRAF p.P453 G 0 0 895 3 0 0 1059 0 0 0 676 2
chr7:140481478 BRAF p.R444 G 0 0 869 2 0 0 1011 1 0 0 722 2
chr7:148508727 EZH2 p.Y646 T 0 0 0 325 0 0 1 374 0 0 0 330
chr7:148508728 EZH2 p.Y646 A 328 0 0 0 375 0 0 0 355 0 0 0
chr7:148508744 EZH2 p.N640 A 396 0 0 0 458 0 0 0 369 1 0 0
chr7:148508757 EZH2 p.P636 G 0 0 395 1 0 0 422 1 0 0 367 0
chr7:55211033 EGFR p.L93 C 0 434 0 0 0 494 0 1 0 697 0 0
chr7:55211034 EGFR p.L93 C 1 438 0 0 0 514 0 0 1 677 0 0
chr7:55211035 EGFR p.L93 T 0 0 0 425 1 0 0 576 0 0 1 701
chr7:55211080 EGFR p.R108 G 0 0 520 0 0 0 582 2 0 0 661 2
chr7:55221821 EGFR p.A289 G 0 0 367 0 0 0 488 1 0 0 769 1
chr7:55221822 EGFR p.A289 C 1 344 0 1 0 467 0 1 0 759 0 0
chr7:55227884 EGFR p.R451 C 0 740 1 0 0 774 0 0 2 584 0 0
chr7:55227885 EGFR p.R451 G 0 0 742 1 0 0 740 1 1 0 591 0
chr7:55227886 EGFR p.R451 C 1 736 0 0 3 778 0 0 0 608 0 0
chr7:55227923 EGFR p.S464 T 0 0 0 815 0 0 0 962 0 0 0 656
chr7:55227924 EGFR p.S464 C 0 827 0 0 0 918 0 0 0 632 0 0
chr7:55227925 EGFR p.S464 A 807 0 0 1 925 0 0 0 627 1 0 0
chr7:55227926 EGFR p.G465 G 0 1 792 0 0 0 842 0 0 0 613 3
chr7:55227927 EGFR p.G465 G 0 0 764 1 0 0 871 0 0 0 647 1
chr7:55227928 EGFR p.G465 A 770 0 0 0 930 0 0 0 680 1 1 0
chr7:55227932 EGFR p.K467 A 782 0 0 0 951 0 1 0 671 1 0 0
chr7:55227933 EGFR p.K467 A 746 0 0 0 940 0 0 0 650 0 0 0
chr7:55227934 EGFR p.K467 A 754 0 0 0 926 0 0 0 657 0 0 0
chr7:55228004 EGFR p.I491 A 636 1 0 0 844 0 0 1 594 0 0 0
chr7:55228005 EGFR p.I491 T 0 0 0 651 0 0 0 850 0 0 0 593
chr7:55228006 EGFR p.I491 A 645 1 0 0 833 0 0 0 598 3 0 1
chr7:55228007 EGFR p.S492 A 607 2 0 0 823 0 0 0 578 1 0 0
chr7:55228008 EGFR p.S492 G 0 0 626 0 0 0 814 0 0 0 579 2
chr7:55228009 EGFR p.S492 C 0 633 0 2 6 795 0 0 1 567 0 0
chr7:55233037 EGFR p.P596 C 0 558 0 0 1 453 0 2 0 485 0 0
chr7:55233043 EGFR p.G598 G 0 0 559 0 0 0 476 0 0 1 483 0
chr7:55241644 EGFR p.A698 G 0 0 577 0 1 0 642 0 0 0 1036 3
chr7:55241656 EGFR p.A702 G 0 0 606 0 0 0 645 0 0 0 1046 2
chr7:55241660 EGFR p.L703 T 0 0 1 552 0 0 2 660 0 0 0 1066
chr7:55241677 EGFR p.E709 G 0 0 568 1 0 0 625 0 0 0 974 3
chr7:55241678 EGFR p.E709 A 558 0 0 1 691 0 0 0 1092 3 0 0
chr7:55241679 EGFR p.E709 A 533 1 0 0 630 0 0 0 960 0 0 1
chr7:55241686 EGFR p.F712 T 0 0 0 543 0 0 0 639 1 0 2 981
chr7:55241687 EGFR p.F712 T 2 0 0 554 0 0 0 660 1 0 1 1029
chr7:55241706 EGFR p.G719 G 0 0 534 1 0 0 547 0 0 0 842 0
chr7:55241707 EGFR p.G719 G 0 0 551 0 0 0 581 0 0 0 972 1
chr7:55241708 EGFR p.G719 G 0 0 554 0 0 0 593 0 0 0 1029 0
chr7:55241711 EGFR p.S720 C 0 528 0 0 0 584 0 0 1 975 0 0
chr7:55241713 EGFR p.G721 G 0 0 543 0 0 0 544 0 1 0 980 2
chr7:55241714 EGFR p.G721 G 0 0 544 0 0 0 563 0 0 0 992 1
chr7:55241722 EGFR p.G724 G 0 0 543 0 0 0 549 0 0 0 878 2
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chr7:55242418 EGFR p.L730 C 0 666 0 0 0 737 0 0 0 810 0 0
chr7:55242423 EGFR p.W731 G 0 0 634 1 0 0 701 1 0 0 781 1
chr7:55242427 EGFR p.P733 C 2 615 0 0 1 702 0 0 3 732 0 0
chr7:55242428 EGFR p.P733 C 0 625 0 0 1 731 0 0 1 735 0 0
chr7:55242430 EGFR p.E734 G 0 1 640 0 0 0 763 0 0 0 759 2
chr7:55242433 EGFR p.G735 G 0 0 613 0 0 0 703 0 0 0 716 3
chr7:55242443 EGFR p.V738 T 0 0 1 612 0 0 1 765 0 0 4 739
chr7:55242452 EGFR p.P741 C 0 601 0 0 0 660 0 0 2 683 1 0
chr7:55242455 EGFR p.V742 T 0 0 0 552 0 0 4 688 1 0 6 683
chr7:55242457 EGFR p.A743 G 0 0 634 0 0 0 683 1 0 0 725 3
chr7:55242464 EGFR p.K745 A 631 1 0 0 785 0 0 0 780 1 0 0
chr7:55242466 EGFR p.E746 G 0 0 627 0 0 1 725 1 0 0 749 0
chr7:55242467 EGFR p.E746 A 671 0 0 0 826 0 0 0 855 0 2 0
chr7:55242468 EGFR p.E746 A 618 2 0 1 791 1 0 0 817 1 0 0
chr7:55242469 EGFR p.L747 T 0 0 1 629 0 0 0 796 0 0 0 812
chr7:55242470 EGFR p.L747 T 0 0 0 637 0 0 0 830 0 0 0 812
chr7:55242471 EGFR p.L747 A 623 0 0 0 810 0 0 0 771 1 0 1
chr7:55242472 EGFR p.R748 A 656 0 0 0 818 0 0 0 792 1 0 0
chr7:55242473 EGFR p.R748 G 0 0 660 0 0 0 757 1 0 0 763 1
chr7:55242474 EGFR p.R748 A 656 0 0 0 794 0 0 0 777 0 0 0
chr7:55242475 EGFR p.E749 G 0 0 662 1 0 0 763 0 0 2 747 1
chr7:55242476 EGFR p.E749 A 608 0 0 1 750 2 0 0 733 1 0 0
chr7:55242477 EGFR p.E749 A 595 1 0 0 754 1 0 0 735 3 0 0
chr7:55242478 EGFR p.A750 G 0 0 640 2 0 1 718 0 0 0 756 2
chr7:55242479 EGFR p.A750 C 1 670 0 0 2 728 0 0 1 775 0 0
chr7:55242480 EGFR p.A750 A 645 1 1 0 781 1 0 0 753 0 1 0
chr7:55242481 EGFR p.T751 A 597 1 0 2 739 0 0 0 725 1 0 0
chr7:55242482 EGFR p.T751 C 0 673 0 0 0 741 0 0 1 796 0 0
chr7:55242483 EGFR p.T751 A 606 2 0 0 741 0 0 0 762 1 0 0
chr7:55242484 EGFR p.S752 T 0 0 0 650 0 0 0 748 0 0 2 778
chr7:55242485 EGFR p.S752 C 0 676 0 0 0 736 0 0 0 771 0 0
chr7:55242486 EGFR p.S752 T 0 0 0 658 0 0 0 761 0 0 0 787
chr7:55242487 EGFR p.P753 C 0 664 0 0 0 692 1 0 3 755 0 0
chr7:55242488 EGFR p.P753 C 2 658 0 0 1 640 0 2 2 703 0 0
chr7:55242489 EGFR p.P753 G 0 0 658 0 0 0 660 1 0 0 724 4
chr7:55242490 EGFR p.K754 A 619 1 0 0 691 2 0 0 734 0 0 0
chr7:55242491 EGFR p.K754 A 599 1 1 0 712 0 0 0 708 2 0 0
chr7:55242492 EGFR p.K754 A 576 1 0 0 695 1 0 0 683 5 1 0
chr7:55242493 EGFR p.A755 G 0 3 626 3 0 0 663 0 0 0 717 2
chr7:55242494 EGFR p.A755 C 0 620 0 0 2 662 0 0 0 740 0 0
chr7:55242495 EGFR p.A755 C 2 608 0 0 1 651 0 0 0 744 0 0
chr7:55242496 EGFR p.A756 A 575 0 0 0 704 1 0 0 716 0 0 0
chr7:55242497 EGFR p.A756 A 552 0 0 0 668 0 0 0 686 0 0 0
chr7:55242498 EGFR p.A756 C 0 599 0 0 0 682 0 0 1 761 0 0
chr7:55242499 EGFR p.K757 A 592 0 0 0 698 0 0 0 719 2 0 0
chr7:55242500 EGFR p.K757 A 584 0 0 1 701 1 0 0 746 3 0 0
chr7:55242501 EGFR p.K757 G 0 0 566 1 0 0 667 1 0 0 679 1
chr7:55242502 EGFR p.E758 G 0 0 589 1 0 0 679 3 0 0 706 2
chr7:55242503 EGFR p.E758 A 599 0 0 0 753 0 0 0 780 2 0 0
chr7:55242504 EGFR p.E758 A 548 4 1 0 701 0 0 0 688 2 0 0
chr7:55242505 EGFR p.I759 A 511 2 0 0 672 0 0 0 668 1 0 0
chr7:55242506 EGFR p.I759 T 0 0 0 566 0 0 0 686 0 0 1 714
chr7:55242511 EGFR p.D761 G 0 0 578 0 0 1 618 2 0 0 684 1
chr7:55242512 EGFR p.D761 A 554 0 0 0 643 0 0 0 695 2 0 0
chr7:55248995 EGFR p.V765 G 0 0 281 1 0 0 340 0 0 1 614 1
chr7:55249002 EGFR p.A767 C 0 295 0 0 0 346 0 0 0 637 0 0
chr7:55249005 EGFR p.S768 G 0 0 299 0 0 0 364 0 0 0 645 0
chr7:55249007 EGFR p.V769 G 0 0 305 0 0 0 347 1 0 0 632 1
chr7:55249010 EGFR p.D770 G 0 0 304 0 0 0 359 0 0 0 636 0
chr7:55249020 EGFR p.H773 A 245 1 1 0 282 4 0 0 543 2 0 0
chr7:55249022 EGFR p.V774 G 0 0 308 0 0 0 334 1 1 0 644 2
chr7:55249026 EGFR p.C775 G 0 0 320 0 1 0 359 0 0 0 653 1
chr7:55249028 EGFR p.R776 C 1 296 0 0 0 309 0 0 3 616 0 0
chr7:55249029 EGFR p.R776 G 0 0 292 0 2 0 330 0 0 0 617 1
chr7:55249037 EGFR p.G779 G 0 0 282 0 0 0 304 0 0 0 576 0
chr7:55249038 EGFR p.G779 G 0 0 292 1 0 0 339 0 0 0 616 1
chr7:55249052 EGFR p.S784 T 0 0 0 352 0 0 0 386 0 0 1 655
chr7:55249053 EGFR p.S784 C 0 386 0 0 1 407 0 0 2 698 0 0
chr7:55249058 EGFR p.V786 G 0 0 384 0 0 0 389 1 0 0 633 4
chr7:55249070 EGFR p.T790 A 378 1 0 1 384 1 0 0 579 6 0 1
chr7:55249071 EGFR p.T790 C 0 449 0 0 0 414 0 0 1 673 0 0
chr7:55249072 EGFR p.T790 G 1 0 436 1 0 0 406 1 1 0 650 0
chr7:55249077 EGFR p.L792 T 1 0 0 467 0 0 0 448 0 0 1 678
chr7:55249130 EGFR p.G810 G 0 0 569 0 0 0 489 0 0 0 815 0
chr7:55249131 EGFR p.G810 G 0 0 576 0 0 0 499 1 0 0 832 1
chr7:55249143 EGFR p.L814 T 1 0 2 572 0 0 0 540 0 0 0 803
chr7:55249159 EGFR p.V819 G 0 0 614 1 0 0 527 0 0 0 821 0
chr7:55249164 EGFR p.I821 T 2 0 2 518 0 0 0 477 0 0 2 753
chr7:55259514 EGFR p.L858 C 2 664 0 0 0 640 0 0 0 898 0 0
chr7:55259515 EGFR p.L858 T 0 0 0 578 0 0 0 590 1 0 2 844
chr7:55259516 EGFR p.L858 G 0 0 613 1 0 0 612 0 0 0 897 1
chr7:55259517 EGFR p.A859 G 0 0 614 1 0 0 607 1 0 1 926 2
chr7:55259524 EGFR p.L861 T 0 0 0 632 0 0 0 682 0 0 3 924
chr7:55259530 EGFR p.G863 G 0 0 630 0 0 0 618 1 0 0 939 2
chr7:55259532 EGFR p.A864 G 0 0 612 2 0 0 584 0 0 0 893 0
chr7:55259545 EGFR p.E868 A 546 0 0 0 577 0 1 1 867 4 0 1
chr7:55259550 EGFR p.H870 C 0 545 0 0 3 529 0 0 1 717 0 0
chr7:55259551 EGFR p.H870 A 543 1 1 0 540 0 0 0 767 1 0 0
chr7:55259553 EGFR p.A871 G 0 0 557 0 0 2 535 0 0 0 811 2
chr7:55259554 EGFR p.A871 C 0 559 0 2 2 515 0 1 2 825 1 0
chr7:55259560 EGFR p.G873 G 1 0 553 0 0 0 535 1 0 0 819 3
chr7:55259562 EGFR p.G874 G 0 0 530 0 0 0 502 1 0 0 779 1
chr8:38282209 FGFR1 p.P252 G 0 0 199 1 0 1 205 0 0 0 127 0
chr8:38285938 FGFR1 p.S125 G 0 0 472 0 0 0 541 0 0 0 517 2
chr9:133738330 ABL1 p.M244 A 237 0 0 1 354 2 0 0 398 2 0 0
chr9:133738342 ABL1 p.L248 C 0 231 0 0 0 311 0 0 0 361 0 0
chr9:133738349 ABL1 p.G250 G 0 0 209 0 0 0 279 1 0 0 324 1
chr9:133738356 ABL1 p.Q252 G 0 0 225 2 0 0 308 0 0 0 323 0
chr9:133738357 ABL1 p.Y253 T 0 0 0 213 0 0 1 299 0 1 0 297
chr9:133738358 ABL1 p.Y253 A 194 0 0 1 306 0 0 0 317 1 0 0
chr9:133738363 ABL1 p.E255 G 0 0 210 1 0 0 289 0 0 0 311 0
chr9:133738364 ABL1 p.E255 A 192 0 1 0 290 0 0 0 292 1 0 0
chr9:133747520 ABL1 p.D276 A 189 0 0 0 268 0 0 0 270 0 0 0
chr9:133748283 ABL1 p.T315 C 0 174 0 0 2 181 0 0 1 169 0 0
chr9:133748288 ABL1 p.F317 T 0 0 0 174 0 0 0 179 0 0 0 165
chr9:133748290 ABL1 p.F317 C 0 189 0 0 1 198 0 0 2 206 0 0
chr9:133748391 ABL1 p.M351 T 0 0 0 149 0 0 1 199 0 0 0 200
chr9:133748403 ABL1 p.E355 A 155 0 0 0 207 0 0 0 184 0 0 0
chr9:133748414 ABL1 p.F359 T 0 0 0 134 0 0 0 170 0 0 0 168
chr9:133750319 ABL1 p.L384 C 1 258 0 0 0 292 0 0 2 263 1 0
chr9:133750328 ABL1 p.L387 T 0 0 1 229 0 1 0 303 0 0 1 255
chr9:133750356 ABL1 p.H396 A 260 0 0 0 303 1 0 0 288 1 0 0
chr9:139390791 NOTCH1 p.S2468 G 0 0 152 1 0 0 149 0 0 0 208 1
chr9:139390816 NOTCH1 p.Q2460 G 0 0 174 0 0 0 131 0 0 0 214 0
chr9:139390873 NOTCH1 p.Q2441 G 0 0 255 1 0 0 213 0 0 0 356 0
chr9:139397768 NOTCH1 p.L1679 A 317 1 0 0 359 0 0 0 598 1 0 0
chr9:139397774 NOTCH1 p.V1677 A 276 2 0 1 314 0 0 0 558 1 0 0
chr9:139399344 NOTCH1 p.L1601 A 201 0 0 0 158 2 0 0 386 0 0 0
chr9:139399350 NOTCH1 p.R1599 C 0 215 0 0 0 177 0 0 3 426 0 0
chr9:139399356 NOTCH1 p.L1597 A 186 1 0 0 171 0 0 0 371 1 0 0
chr9:139399365 NOTCH1 p.L1594 A 224 0 0 0 207 1 0 0 384 0 0 0
chr9:139399368 NOTCH1 p.F1593 A 214 0 0 0 209 0 0 0 390 3 0 0
chr9:139399389 NOTCH1 p.L1586 A 167 1 0 0 185 0 0 0 340 1 0 0
chr9:139399416 NOTCH1 p.V1577 A 135 0 0 0 183 0 0 0 288 0 0 0
chr9:139399422 NOTCH1 p.L1575 A 137 0 0 1 217 0 0 0 294 3 0 0
chr9:21970962 CDKN2A p.A132 C 0 237 0 0 2 245 0 1 0 342 0 0
chr9:21970964 CDKN2A p.A132 C 0 258 0 0 0 274 0 0 4 360 0 0
chr9:21970966 CDKN2A p.R131 C 1 254 0 0 0 294 0 0 0 402 0 0
chr9:21970968 CDKN2A p.L130 C 0 254 0 1 0 298 0 0 0 421 0 1
chr9:21970969 CDKN2A p.L130 A 237 0 0 1 306 0 0 0 355 1 0 0
chr9:21970971 CDKN2A p.Y129 G 0 0 260 0 0 0 301 0 0 0 410 0
chr9:21970972 CDKN2A p.Y129 T 0 0 2 230 0 0 0 296 0 0 1 348
chr9:21970976 CDKN2A p.R128 G 0 0 262 0 1 0 296 0 0 0 436 0
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chr9:21970980 CDKN2A p.V126 G 0 0 265 0 1 0 288 0 0 0 407 1
chr9:21970982 CDKN2A p.V126 C 0 257 0 0 0 299 0 0 2 444 0 0
chr9:21970985 CDKN2A p.D125 C 0 253 0 0 0 292 0 0 0 419 0 0
chr9:21970987 CDKN2A p.R124 C 0 255 0 0 0 288 0 0 1 427 0 0
chr9:21970989 CDKN2A p.H123 A 235 0 0 0 251 0 0 0 366 3 0 0
chr9:21970992 CDKN2A p.G122 G 0 0 261 0 0 0 285 0 0 0 422 0
chr9:21970993 CDKN2A p.G122 C 0 265 0 0 0 290 0 0 1 431 0 0
chr9:21970994 CDKN2A p.G122 C 0 257 0 0 0 293 0 0 0 433 0 0
chr9:21971000 CDKN2A p.E120 C 0 256 0 0 0 289 0 0 2 471 0 0
chr9:21971003 CDKN2A p.E119 C 2 260 0 0 1 276 0 0 0 472 0 0
chr9:21971012 CDKN2A p.D116 C 0 246 0 0 1 266 0 0 0 530 0 0
chr9:21971015 CDKN2A p.V115 C 0 236 0 0 0 249 0 0 0 502 0 2
chr9:21971017 CDKN2A p.P114 G 0 0 230 1 0 0 223 0 0 0 438 0
chr9:21971018 CDKN2A p.P114 G 0 0 234 1 0 0 251 0 0 0 487 0
chr9:21971024 CDKN2A p.R112 G 0 0 214 0 0 0 219 0 0 0 467 0
chr9:21971028 CDKN2A p.W110 C 0 220 0 0 0 233 0 0 0 497 0 0
chr9:21971029 CDKN2A p.W110 C 0 229 0 0 0 238 0 0 0 540 0 0
chr9:21971036 CDKN2A p.D108 C 0 212 0 0 1 226 0 0 0 496 0 0
chr9:21971040 CDKN2A p.V106 C 0 209 0 0 2 217 0 0 1 509 0 0
chr9:21971042 CDKN2A p.V106 C 0 215 0 1 0 229 0 0 0 530 0 0
chr9:21971053 CDKN2A p.A102 G 0 0 222 0 1 0 223 1 0 0 499 0
chr9:21971055 CDKN2A p.G101 C 0 216 0 0 0 221 0 0 0 509 0 0
chr9:21971060 CDKN2A p.A100 C 0 221 0 0 0 237 0 0 1 533 0 0
chr9:21971107 CDKN2A p.D84 T 0 0 0 187 0 0 3 151 0 0 6 340
chr9:21971108 CDKN2A p.D84 C 0 241 0 0 0 218 0 0 0 500 0 0
chr9:21971110 CDKN2A p.H83 T 0 0 2 175 0 0 0 166 1 0 3 365
chr9:21971111 CDKN2A p.H83 G 0 0 230 0 0 0 212 0 0 0 503 0
chr9:21971114 CDKN2A p.V82 C 0 210 0 0 1 191 0 0 1 441 0 0
chr9:21971116 CDKN2A p.P81 G 0 0 219 0 0 0 205 0 0 0 483 0
chr9:21971119 CDKN2A p.R80 C 0 216 0 0 0 192 0 0 0 395 0 0
chr9:21971120 CDKN2A p.R80 G 0 0 208 0 0 0 189 0 0 0 431 0
chr9:21971121 CDKN2A p.T79 G 0 0 214 0 0 0 206 0 0 0 466 0
chr9:21971122 CDKN2A p.T79 G 0 0 216 0 0 0 212 0 0 0 489 0
chr9:21971131 CDKN2A p.A76 G 0 0 205 0 0 0 207 0 0 0 465 1
chr9:21971134 CDKN2A p.P75 G 0 0 202 0 0 0 204 0 0 0 438 0
chr9:21971136 CDKN2A p.D74 G 0 0 205 0 0 0 207 0 0 0 459 0
chr9:21971137 CDKN2A p.D74 T 0 0 0 165 0 0 2 142 0 0 6 274
chr9:21971138 CDKN2A p.D74 C 0 205 0 0 0 211 0 0 0 418 0 0
chr9:21971142 CDKN2A p.C72 G 0 0 205 1 1 0 190 0 0 0 426 0
chr9:21971145 CDKN2A p.N71 G 0 0 210 0 0 0 193 0 0 0 464 0
chr9:21971149 CDKN2A p.P70 G 0 0 197 0 0 0 213 0 2 0 433 1
chr9:21971152 CDKN2A p.E69 T 0 0 0 169 0 0 0 164 0 0 3 335
chr9:21971153 CDKN2A p.E69 C 0 197 0 0 1 205 0 0 0 420 0 0
chr9:21971154 CDKN2A p.A68 C 0 204 0 0 0 199 0 0 1 396 0 0
chr9:21971155 CDKN2A p.A68 G 0 0 198 0 0 0 206 0 0 0 428 0
chr9:21971156 CDKN2A p.A68 C 1 202 0 0 0 206 0 0 0 426 0 0
chr9:21971158 CDKN2A p.G67 C 0 192 0 2 0 192 0 0 0 405 0 0
chr9:21971159 CDKN2A p.G67 C 0 198 0 0 0 194 0 0 0 391 0 0
chr9:21971161 CDKN2A p.H66 T 0 0 0 158 0 0 0 157 0 1 2 306
chr9:21971164 CDKN2A p.L65 A 160 0 0 0 163 0 0 0 349 1 0 0
chr9:21971166 CDKN2A p.L64 C 0 192 0 0 0 202 0 0 2 439 0 0
chr9:21971170 CDKN2A p.L63 A 156 1 0 1 157 1 0 0 325 0 0 0
chr9:21971171 CDKN2A p.L63 G 0 0 193 0 0 0 195 0 1 0 414 0
chr9:21971177 CDKN2A p.E61 C 0 184 0 0 0 178 0 0 0 399 0 0
chr9:21971179 CDKN2A p.A60 G 0 0 198 0 0 0 194 1 0 0 422 1
chr9:21971186 CDKN2A p.R58 G 0 0 190 0 0 0 151 0 0 0 372 0
chr9:21971187 CDKN2A p.A57 G 0 0 190 0 0 0 170 0 0 0 399 0
chr9:21971188 CDKN2A p.A57 G 0 0 194 0 0 0 188 0 0 0 426 0
chr9:21971189 CDKN2A p.A57 C 0 194 0 1 0 184 0 0 0 427 0 0
chr9:21971202 CDKN2A p.M52 C 0 198 0 0 1 183 0 0 2 392 0 0
chr9:21971203 CDKN2A p.M52 A 170 0 0 0 156 0 0 0 361 0 0 0
chr9:21971206 CDKN2A p.V51 A 156 0 0 0 129 1 0 0 317 3 0 0
chr9:21971207 CDKN2A p.V51 C 0 193 0 0 0 170 0 0 0 386 0 0
chr9:5073752 JAK2 p.L611 T 0 0 0 303 0 0 0 385 0 0 2 313
chr9:5073769 JAK2 p.C616 T 0 0 0 271 0 0 0 349 0 0 0 254
chr9:5073770 JAK2 p.V617 G 0 0 263 0 0 0 323 1 0 0 255 1
chr9:5073773 JAK2 p.C618 T 0 0 0 252 0 0 0 343 0 0 0 213
chr9:5073781 JAK2 p.D620 C 0 236 0 0 1 272 0 0 0 165 0 0
chr9:80409487 GNAQ p.Q209 T 0 0 0 165 0 0 0 240 0 0 0 284
chr9:80409488 GNAQ p.Q209 T 0 0 0 159 0 0 0 236 0 0 0 279
chr9:80409489 GNAQ p.Q209 G 0 0 169 0 0 0 208 0 0 0 275 2
chrX:47429340 ARAF p.S490 T 0 0 0 172 0 0 0 170 0 0 1 205
chrX:47429341 ARAF p.S490 C 0 202 0 0 0 198 0 0 1 229 0 0
chrX:47429342 ARAF p.S490 A 187 0 0 0 191 0 0 0 225 0 0 0
chrX:70341430 MED12 p.Q289 C 0 183 0 0 0 291 0 0 2 319 0 0
chrX:70341431 MED12 p.Q289 A 181 0 0 0 291 0 0 0 319 0 0 0
chrX:70341432 MED12 p.Q289 G 0 0 187 0 0 0 299 1 0 0 326 1
chrX:70346290 MED12 p.E881 G 0 0 263 0 0 0 296 0 0 0 427 2
chrX:70346291 MED12 p.E881 A 249 0 2 0 292 0 0 0 407 0 0 0
chrX:70346292 MED12 p.E881 A 244 0 0 2 308 0 0 0 430 1 0 0
chrX:70350002 MED12 p.R1329 C 0 150 0 0 0 125 0 2 2 135 0 0
chrX:70350003 MED12 p.R1329 G 0 0 158 0 0 0 118 0 0 0 136 0
chrX:70350004 MED12 p.R1329 A 142 3 0 0 114 0 0 0 123 0 0 0
chrX:70352768 MED12 p.E1497 G 0 0 130 0 0 0 124 0 0 0 153 0
chrX:70352769 MED12 p.E1497 A 121 0 0 0 129 0 0 0 148 0 0 0
chrX:70352770 MED12 p.E1497 G 0 0 131 0 0 0 123 1 0 0 148 0
chrX:70355014 MED12 p.R1646 C 1 273 0 0 0 213 0 0 1 127 0 0
chrX:70355015 MED12 p.R1646 G 0 0 268 0 0 0 217 0 0 0 132 0
chrX:70355016 MED12 p.R1646 A 271 1 0 0 224 0 0 0 132 0 0 0
chrX:70356167 MED12 p.W1688 T 0 0 0 265 0 0 0 340 0 0 0 327
chrX:70356168 MED12 p.W1688 G 0 0 265 0 0 0 337 0 0 0 333 0
chrX:70356169 MED12 p.W1688 G 0 0 276 2 0 0 334 0 0 0 342 1
chr7:116339642 MET p.E168 G 0 0 972 0 0 0 3276 8 0 0 1011 0
chr7:116340262 MET p.N375 A 380 2 0 0 2104 0 0 1 575 2 0 1
chr7:116403228 MET p.Y848 A 1368 1 0 0 5295 0 1 7 1665 3 0 1
chr7:116411923 MET p.R988 C 3 1125 0 0 9 3921 0 0 2 1608 0 0
chr7:116411990 MET p.T1010 C 1 1313 0 0 1 4885 0 0 0 2018 0 0
chr7:116415156 MET p.I1102 A 991 0 0 0 3966 0 0 0 1706 3 1 0
chr7:116415157 MET p.I1102 T 1 0 2 989 1 0 2 3977 1 0 3 1619
chr7:116415158 MET p.I1102 A 1003 0 0 1 3929 0 0 0 1647 0 0 1
chr7:116417457 MET p.V1110 G 0 0 712 0 0 0 3296 3 0 0 1502 4
chr7:116417458 MET p.V1110 T 0 0 1 684 0 0 1 3449 1 0 7 1523
chr7:116417459 MET p.V1110 A 698 0 0 0 3424 0 0 1 1568 1 0 1
chr7:116417463 MET p.H1112 C 1 718 0 0 6 3274 4 0 0 1532 0 0
chr7:116417464 MET p.H1112 A 695 1 0 1 3391 1 0 2 1504 1 0 1
chr7:116417479 MET p.D1117 A 672 0 2 0 3269 0 0 0 1538 2 0 0
chr7:116417481 MET p.N1118 A 703 0 0 0 3406 0 0 1 1530 0 0 2
chr7:116417499 MET p.H1124 C 0 702 0 0 3 3210 1 0 2 1505 0 0
chr7:116417511 MET p.K1128 A 733 0 0 1 3378 0 2 0 1600 0 0 0
chr7:116417512 MET p.K1128 A 696 1 0 0 3292 0 0 0 1512 0 0 0
chr7:116417513 MET p.K1128 A 684 2 0 0 3217 1 0 0 1519 1 0 0
chr7:116417519 MET p.L1130 G 0 0 652 0 0 0 2951 4 0 0 1445 0
chr7:116418958 MET p.L1175 C 2 913 0 0 8 3010 0 0 2 1280 0 0
chr7:116418959 MET p.L1175 T 0 0 1 907 0 1 1 3236 0 0 0 1332
chr7:116418960 MET p.L1175 A 889 1 0 0 3165 3 0 2 1332 2 0 1
chr7:116418964 MET p.L1177 T 0 0 0 911 0 1 0 3350 0 0 0 1286
chr7:116418965 MET p.L1177 A 926 0 0 1 3427 0 0 2 1379 0 0 0
chr7:116418966 MET p.L1177 C 0 959 0 0 12 3281 3 2 2 1344 0 0
chr7:116418967 MET p.L1178 A 965 0 0 0 3497 0 1 0 1384 1 0 0
chr7:116418968 MET p.L1178 T 0 0 0 936 0 4 0 3446 1 0 2 1330
chr7:116418969 MET p.L1178 G 0 0 965 0 2 1 3329 2 2 0 1257 1
chr7:116422150 MET p.M1229 A 1340 0 0 1 5007 2 0 0 1546 1 0 0
chr7:116422151 MET p.M1229 T 0 1 0 1314 3 1 3 4967 0 0 1 1604
chr7:116423358 MET p.M1229 G 0 0 1055 2 0 1 4297 9 0 0 1470 2
chr7:116423389 MET p.D1240 G 0 0 1337 1 1 0 4973 5 0 0 1442 2
chr7:116423390 MET p.D1240 A 1295 1 0 0 5401 1 0 0 1493 0 0 2
chr7:116423391 MET p.D1240 T 0 0 2 1224 0 1 6 5237 0 0 0 1455
chr7:116423401 MET p.A1244 G 0 0 1276 0 2 3 4835 7 1 0 1475 2
chr7:116423402 MET p.A1244 C 3 1234 0 0 10 4648 1 0 5 1451 1 0
chr7:116423403 MET p.A1244 C 0 1219 0 1 9 4556 2 0 3 1393 0 1
chr7:116423407 MET p.D1246 G 0 0 1310 0 0 0 4802 5 0 0 1536 1
chr7:116423408 MET p.D1246 A 1220 0 0 0 4885 3 3 1 1528 2 0 1
chr7:116423409 MET p.D1246 C 1 1253 0 0 14 4818 2 2 2 1477 0 0
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Supplementary Table 1
COORDINATES GENE AA_CHANGE REF A1 C1 G1 T1 A2 C2 G2 T2 A2 C2 G2 T2
PLASMA AT BASELINE TO VEMURAFENIB+CRIZOTINIB PLASMA AT RESISTANCE TO VEMURAFENIB+CRIZOTINIB LIVER BIOPSY AT RESISTANCE TO VEMURAFENIB+CRIZOTINIB
# READS
chr7:116423413 MET p.Y1248 T 0 0 0 1265 1 0 3 5250 0 0 2 1519
chr7:116423414 MET p.Y1248 A 1233 1 0 0 5126 1 2 1 1488 1 0 0
chr7:116423415 MET p.Y1248 T 0 0 0 1278 0 0 2 5159 1 0 0 1528
chr7:116423428 MET p.Y1253 T 1 0 0 1223 0 0 1 5259 0 0 0 1648
chr7:116423474 MET p.M1268 T 0 0 3 1358 0 1 5 5709 0 0 4 1481
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